<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005128.pub3" GROUP_ID="RENAL" ID="134904042911245101" MERGED_FROM="" MODIFIED="2015-08-02 08:13:16 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="008" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.3">
<COVER_SHEET MODIFIED="2015-08-02 08:13:16 +0100" MODIFIED_BY="Narelle Willis">
<TITLE MODIFIED="2009-04-16 16:23:12 +1000" MODIFIED_BY="Narelle S Willis">Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)</TITLE>
<CONTACT MODIFIED="2015-08-02 08:13:16 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="16110" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elisabeth</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Hodson</LAST_NAME><EMAIL_1>elisabeth.hodson@health.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Kidney Research</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451469</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-08-02 08:13:16 +0100" MODIFIED_BY="Narelle Willis"><PERSON ID="37118364179006849546100524045306" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Deirdre</FIRST_NAME><LAST_NAME>Hahn</LAST_NAME><POSITION>Senior Staff Specialist</POSITION><EMAIL_1>Deirdre.hahn@health.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Department of Nephrology</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98453430</PHONE_1><FAX_1>+61 2 98453432</FAX_1></ADDRESS></PERSON><PERSON ID="16110" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elisabeth</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Hodson</LAST_NAME><EMAIL_1>elisabeth.hodson@health.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>Centre for Kidney Research</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451469</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></PERSON><PERSON ID="9199" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Narelle</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Willis</LAST_NAME><POSITION>Managing Editor</POSITION><EMAIL_1>narelle.willis@health.nsw.gov.au</EMAIL_1><URL>http://www.cochrane-renal.org</URL><ADDRESS><DEPARTMENT>Cochrane Kidney and Transplant, Centre for Kidney Research</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead</ORGANISATION><ADDRESS_1>Locked Bag 4001</ADDRESS_1><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451478</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></PERSON><PERSON ID="4552" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jonathan</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Craig</LAST_NAME><EMAIL_1>jonathan.craig@sydney.edu.au</EMAIL_1><EMAIL_2>JonC@health.usyd.edu.au</EMAIL_2><ADDRESS><DEPARTMENT>Sydney School of Public Health</DEPARTMENT><ORGANISATION>The University of Sydney</ORGANISATION><ADDRESS_1>Edward Ford Building A27</ADDRESS_1><CITY>Sydney</CITY><ZIP>2006</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-07-30 11:56:12 +1000" MODIFIED_BY="Elisabeth Hodson">
<UP_TO_DATE>
<DATE DAY="13" MONTH="7" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="7" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="13" MONTH="1" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-07-21 15:46:19 +1000" MODIFIED_BY="Narelle S Willis">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-07-21 15:44:27 +1000" MODIFIED_BY="Narelle S Willis">
<DATE DAY="21" MONTH="7" YEAR="2015"/>
<DESCRIPTION>
<P>New studies identified</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-07-21 15:46:19 +1000" MODIFIED_BY="Narelle S Willis">
<DATE DAY="21" MONTH="7" YEAR="2015"/>
<DESCRIPTION>
<P>New study investigating treatment for severe kidney disease in adults included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-07-13 14:42:57 +1000" MODIFIED_BY="Narelle Willis">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-07-13 14:42:57 +1000" MODIFIED_BY="Narelle Willis">
<DATE DAY="18" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-06-16 17:37:15 +1000" MODIFIED_BY="Narelle S Willis">
<DATE DAY="16" MONTH="6" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-08-02 17:08:16 +1000" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2015-07-21 16:38:28 +1000" MODIFIED_BY="Narelle S Willis">
<TITLE MODIFIED="2015-07-21 16:38:28 +1000" MODIFIED_BY="Narelle S Willis">Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura</TITLE>
<SUMMARY_BODY MODIFIED="2015-07-21 15:42:22 +1000" MODIFIED_BY="Narelle S Willis">
<P>Henoch-Schönlein Purpura (HSP) causes inflammation of small blood vessels in children and affects approximately 20/100,000 children annually. Symptoms and signs include a purpuric skin rash (which comprises small spots and larger bruises), abdominal pain, gastrointestinal bleeding, joint pain and swelling, facial swelling and evidence of kidney disease with blood and protein in the urine. Kidney disease occurs in about one third of children with HSP. In the majority this is mild (small amounts of blood in the urine only) and resolves completely but a few children have persistent kidney disease that can progress to kidney failure.</P>
<P>This review identified 13 studies (1403 participants) investigating interventions for either preventing persistent HSP-associated kidney disease or treating severe kidney disease. Five studies (856 enrolled children) which compared prednisone tablets given for 14 to 28 days with placebo tablets or no specific treatment for the prevention of persistent kidney disease at 6 to 12 months after onset of HSP. No significant reduction in the frequency of persistent kidney disease was demonstrated. Two studies (129 children) showed no benefit of aspirin and dipyridamole (antiplatelet agents) to prevent persistent kidney disease. One study (228 children) suggested that heparin given by injection could reduce the risk for persistent kidney disease but this treatment has the potential side effect of severe bleeding so its administration is not justified when only one third of children develop any kidney disease and in most this is not serious and resolves completely. There appeared to be no serious side effects in these studies but information provided on side effects was limited.</P>
<P>In patients with serious kidney disease, two studies (one in adults and one in children) showed that cyclophosphamide was no more effective than placebo or supportive treatment in preventing progressive kidney injury. Two small studies comparing cyclosporin with methylprednisolone/prednisone (15 children) and mycophenolate mofetil with azathioprine (17 children) found no significant benefits of cyclosporin or mycophenolate. However the numbers of children studied were too small to completely exclude a benefit so further studies are required. No serious side effects were reported.</P>
<P>There are few data from randomised controlled studies examining interventions used to prevent or treat serious kidney disease in HSP except for short-term prednisone to prevent kidney disease. There was no evidence of benefit of short courses of prednisone in preventing serious kidney disease in HSP.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND MODIFIED="2015-07-21 16:16:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>Henoch-Schönlein purpura (HSP) is the most common vasculitis of childhood but may occur in adults. This small vessel vasculitis is characterised by palpable purpura, abdominal pain, arthritis or arthralgia and kidney involvement. This is an update of a review first published in 2009.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-07-21 15:20:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>To evaluate the benefits and harms of different agents (used singularly or in combination) compared with placebo, no treatment or any other agent for: (1) the prevention of severe kidney disease in patients with HSP without kidney disease at presentation; (2) the prevention of severe kidney disease in patients with HSP and minor kidney disease (microscopic haematuria, mild proteinuria) at presentation; (3) the treatment of established severe kidney disease (macroscopic haematuria, proteinuria, nephritic syndrome, nephrotic syndrome with or without acute kidney failure) in HSP; and (4) the prevention of recurrent episodes of HSP-associated kidney disease.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-07-24 16:23:45 +1000" MODIFIED_BY="Narelle S Willis">
<P>We searched the Cochrane Kidney and Transplant's Specialised Register to 13 July 2015 through contact with the Trials Search Co-ordinator using search terms relevant to this review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-07-21 11:58:24 +1000" MODIFIED_BY="Narelle S Willis">
<P>Randomised controlled trials (RCTs) comparing interventions used to prevent or treat kidney disease in HSP compared with placebo, no treatment or other agents were included.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-01-10 14:42:37 +1100" MODIFIED_BY="[Empty name]">
<P>Two authors independently determined study eligibility, assessed risk of bias and extracted data from each study. Statistical analyses were performed using the random effects model and the results were expressed as risk ratio (RR) or risk difference (RD) for dichotomous outcomes and mean difference (MD) for continuous outcomes with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Thirteen studies (1403 enrolled patients) were identified. Risks of bias attributes were frequently poorly performed. Low risk of bias was reported in six studies (50%) for sequence generation (selection bias) and in seven (58%) for allocation concealment (selection bias). Blinding of participants and personnel (performance bias) and of outcome assessment (detection bias) was at low risk of bias in three studies. Five studies reported complete outcome data (attrition bias) while eight studies reported expected outcomes so were at low risk of reporting bias.</P>
<P>Eight studies evaluated therapy to prevent persistent kidney disease in HSP. There was no significant difference in the risk of persistent kidney disease any time after treatment (5 studies, 746 children: RR 0.74, 95% CI 0.42 to 1.32), or at one, three, six and 12 months in children given prednisone for 14 to 28 days at presentation of HSP compared with placebo or supportive treatment. There were no significant differences in the risk of persistent kidney disease with antiplatelet therapy in children with or without kidney disease at entry. Heparin significantly reduced the risk of persistent kidney disease by three months compared with placebo (1 study, 228 children: RR 0.27, 95% CI 0.14 to 0.55); no significant bleeding occurred. Four studies examined the treatment of severe HSP-associated kidney disease. Two studies (one involving 56 children and the other involving 54 adults) compared cyclophosphamide with placebo or supportive treatment and found no significant benefit of cyclophosphamide. There were no significant differences in adverse effects. In one study comparing cyclosporin with methylprednisolone (15 children) there was no significant difference in remission at final follow-up at a mean of 6.3 years (RR 1.37, 95% CI 0.74 to 2.54). In one study (17 children) comparing mycophenolate mofetil with azathioprine, there was no significant difference in the remission of proteinuria at one year (RR 1.32, 95% CI 0.86 to 2.03). No studies were identified which evaluated the efficacy of therapy on kidney disease in participants with recurrent episodes of HSP.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-07-21 15:54:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>There are no substantial changes in conclusions from this update compared with the initial review. From generally low quality evidence, we found no evidence of benefit from RCTs for the use of prednisone or antiplatelet agents to prevent persistent kidney disease in children with HSP. Though heparin appeared effective, this potentially dangerous therapy is not justified to prevent serious kidney disease when fewer than 2% of children with HSP develop severe kidney disease. No evidence of benefit has been found for cyclophosphamide treatment in children or adults with HSP and severe kidney disease. Because of small patient numbers and events leading to imprecision in results, it remains unclear whether cyclosporin and mycophenolate mofetil have any roles in the treatment of children with HSP and severe kidney disease.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-08-02 17:07:20 +1000" MODIFIED_BY="Narelle S Willis">
<BACKGROUND MODIFIED="2015-07-21 16:57:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<BR/>
</P>
<CONDITION MODIFIED="2015-07-21 16:53:11 +1000" MODIFIED_BY="Narelle S Willis">
<P>Henoch-Schönlein Purpura (HSP) is a primary small vessel, non-granulomatous vasculitis. It is the most common systemic vasculitis in children occurring between the ages of three and 15 years, although adults may also be affected. The annual incidence in a UK population based study was 20/100,000 in children &lt; 17 years of age with a peak incidence of 70/100,000 in children between four and six years of age (<LINK REF="REF-Gardner_x002d_Medwin-2002" TYPE="REFERENCE">Gardner-Medwin 2002</LINK>). Clinically the disease is characterised by a tetrad of features including palpable purpura, arthritis or arthralgia, abdominal pain and kidney disease (<LINK REF="REF-Saulsbury-1999" TYPE="REFERENCE">Saulsbury 1999</LINK>). According to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides HSP, (IgA vasculitis) is classified as vasculitis with IgA<SUB>1</SUB>-dominant immune deposits affecting small vessels, predominantly capillaries, venules or arterioles (<LINK REF="REF-Jennette-2013" TYPE="REFERENCE">Jennette 2013</LINK>). Glomerulonephritis (GN) is the major complication of HSP. Kidney involvement is clinically manifested by microscopic or macroscopic haematuria, proteinuria, nephrotic syndrome and reduced kidney function. In a systematic review of studies (<LINK REF="REF-Narchi-2005" TYPE="REFERENCE">Narchi 2005</LINK>) of unselected patients, kidney involvement occurred in 34% of children; 80% had isolated haematuria, proteinuria or both while 20% had acute nephritic syndrome or nephrotic syndrome. Kidney disease, if it did occur, developed early - by four weeks in 85% and by six months in nearly all children. Persistent kidney disease (hypertension, reduced function, nephrotic or nephritic syndrome) occurred in 1.8% of children overall but the incidence varied with the severity of the kidney disease at presentation. In general, the prognosis for long-term kidney function in HSP is excellent in children with microscopic or macroscopic haematuria alone. However patients with nephrotic syndrome and reduced kidney function frequently show a progressive course to end-stage kidney disease (ESKD). In a study of 78 children with HSP and kidney involvement presenting to two paediatric nephrology services, 44% of children presenting with acute nephritic syndrome, nephrotic syndrome or both compared with 13% presenting with haematuria, proteinuria or both had hypertension or impaired kidney function at a mean follow-up of 23.4 years (<LINK REF="REF-Goldstein-1992" TYPE="REFERENCE">Goldstein 1992</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-07-21 16:15:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>Corticosteroid therapy is commonly used in the acute phase of HSP, particularly for abdominal pain. Controversy has existed as to whether corticosteroids can prevent the development of kidney involvement, reduce its severity or both in HSP. One systematic review concluded that early corticosteroid therapy may reduce the risk of developing persistent kidney disease (<LINK REF="REF-Weiss-2007" TYPE="REFERENCE">Weiss 2007</LINK>). However two other systematic reviews concluded that the benefit of corticosteroids in preventing persistent kidney disease remained unproven (<LINK REF="REF-Wyatt-2001" TYPE="REFERENCE">Wyatt 2001</LINK>; <LINK REF="REF-Zaffanello-2007" TYPE="REFERENCE">Zaffanello 2007</LINK>). There is also considerable uncertainty about the efficacy of therapies to prevent progression to chronic or ESKD in children with HSP-associated acute nephritis or nephrotic syndrome. Corticosteroid therapy, azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporin, antiplatelet therapy, anticoagulants and plasmapheresis have been used in such patients (<LINK REF="REF-Bergstein-1998" TYPE="REFERENCE">Bergstein 1998</LINK>; <LINK REF="REF-Du-2012" TYPE="REFERENCE">Du 2012</LINK>; <LINK REF="REF-Flynn-2001" TYPE="REFERENCE">Flynn 2001</LINK>; <LINK REF="REF-Foster-2000" TYPE="REFERENCE">Foster 2000</LINK>; <LINK REF="REF-Iijima-1998" TYPE="REFERENCE">Iijima 1998</LINK>; <LINK REF="REF-Niaudet-1998" TYPE="REFERENCE">Niaudet 1998</LINK>; <LINK REF="REF-Ronkainen-2003" TYPE="REFERENCE">Ronkainen 2003</LINK>; <LINK REF="REF-Shenoy-2007" TYPE="REFERENCE">Shenoy 2007</LINK>) with varying results. However the data come from largely from observational studies rather than from randomised controlled trials (RCTs).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-01-23 12:43:55 +1100" MODIFIED_BY="[Empty name]">
<P>HSP nephritis (HSPN) is due to a systemic vasculitis with deposition of immune deposits of IgA<SUB>1</SUB> in the mesangium, activation of the alternative complement pathway and inflammation. Therefore it is has been argued that medications, which treat other immune diseases including kidney diseases, would have a role in preventing or treating HSPN. In particular it was postulated that corticosteroids could prevent the development of significant HSPN in children presenting with HSP. The use of other immunosuppressive agents is based on their efficacy in preventing kidney transplant rejection and in treating other immune complex diseases such as systemic lupus erythematosus. Urokinase, dipyridamole and warfarin have been used because of their roles in inhibiting the mediators of glomerular damage (<LINK REF="REF-Kawasaki-2004" TYPE="REFERENCE">Kawasaki 2004</LINK>). Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-receptor blockers (ARB) would be expected to reduce proteinuria via effects on intraglomerular haemodynamics.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-07-21 16:57:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>Although multiple treatment modalities have been used to prevent or to treat HSPN, there is no consensus on the efficacy of various therapies. The aims of this systematic review were to determine the benefits and harms of different interventions used to prevent or treat persistent kidney disease in HSP in children and adults. The scope was deliberately broad because RCTs in HSP are few, and variability in the spectrum of kidney disease included in the relevant studies was very likely. This update of this systematic review, originally published in 2009 (<LINK REF="REF-Chartapisak-2009" TYPE="REFERENCE">Chartapisak 2009</LINK>), aimed to incorporate any further data from RCTs to provide additional evidence for or against the use of corticosteroids or other therapies to prevent HSPN, for or against the use of immunosuppressive agents to treat established HSPN and to determine the efficacy of ACEi or ARB in reducing proteinuria.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-07-21 11:29:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>To evaluate the benefits and harms of different agents (used singularly or in combination) compared with placebo, no treatment or any other agent for:<BR/>
</P>
<UL>
<LI>The prevention of severe kidney disease in patients with HSP without kidney disease at presentation.</LI>
<LI>The prevention of severe kidney disease in patients with HSP and minor kidney disease (microscopic haematuria, mild proteinuria) at presentation.</LI>
<LI>The treatment of established severe kidney disease (macroscopic haematuria, proteinuria, nephritic syndrome, nephrotic syndrome with or without acute kidney failure) in HSP.</LI>
<LI>The prevention of recurrent episodes of HSP-associated kidney disease.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2015-08-02 17:07:20 +1000" MODIFIED_BY="Narelle S Willis">
<SELECTION_CRITERIA MODIFIED="2015-08-02 17:07:20 +1000" MODIFIED_BY="Narelle S Willis">
<CRIT_STUDIES MODIFIED="2009-04-20 09:53:08 +1000" MODIFIED_BY="[Empty name]">
<P>All RCTs and quasi-RCTS (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) looking at the benefits and harms of different therapeutic modalities for the prevention or treatment of kidney disease in HSP. If crossover studies were identified, the first period of randomised crossover studies were to be included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-08-02 17:07:04 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>Patients of any age with HSP with or without kidney disease manifestations (microscopic haematuria, macroscopic haematuria, proteinuria, nephrotic syndrome, acute nephritic syndrome, reduced function, acute kidney failure).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<P>Patients with other forms of primary or secondary GN such as IgA nephropathy, mesangiocapillary GN, membranous GN, systemic lupus erythematosus, rapidly progressive GN not associated with HSP, other systemic vasculitides.</P>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-08-02 17:07:20 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Immunosuppressive agents including corticosteroids, alkylating agents (cyclophosphamide, chlorambucil), azathioprine, mycophenolate, cyclosporin and rituximab</LI>
<LI>Anticoagulants and antiplatelet agents including warfarin, dipyridamole, aspirin, heparin</LI>
<LI>ACEi and ARB</LI>
<LI>Fish oil</LI>
<LI>Immunoglobulin G, plasma exchange, antibody therapy</LI>
<LI>The above agents used individually or in combination were compared with placebo or no specific therapy or compared with other agents</LI>
<LI>Different durations, frequencies or modes of delivery of the same interventions.</LI>
</OL>
<P>Studies of therapies with herbal treatments and non-pharmacological interventions were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-07-21 16:59:28 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>ESKD (including dialysis and transplantation)</LI>
<LI>Significant increase in serum creatinine (SCr) as defined by the investigators</LI>
<LI>Significant reduction in glomerular filtration rate (GFR) as defined by the investigators</LI>
<LI>Hypertension due to HSP-associated kidney disease</LI>
<LI>Development, persistence or worsening of proteinuria as defined by the investigators</LI>
<LI>The development or persistence of nephrotic syndrome, nephritic syndrome, acute kidney insufficiency</LI>
<LI>Patient mortality</LI>
<LI>Biopsy result including percent of crescent formation, chronicity index, sclerosis, and fibrosis</LI>
<LI>Quality of life</LI>
<LI>Complications of therapy e.g. infection, bleeding, neutropenia, hypertension.</LI>
</OL>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-07-21 16:58:53 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Reduction in kidney function including ESKD, acute kidney insufficiency or significant increase in SCr, GFR or both as defined by the investigators</LI>
<LI>Development, persistence or worsening of proteinuria, development of nephrotic syndrome or acute nephritic syndrome as defined by the investigators</LI>
<LI>Complications of therapy including infection, bleeding, leucopenia, hypertension</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-07-21 15:56:26 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Biopsy result including percent of crescent formation, chronicity index, sclerosis, and fibrosis.</LI>
<LI>Quality of life</LI>
<LI>Hypertension due to HSP-associated kidney disease</LI>
<LI>Patient mortality</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<ELECTRONIC_SEARCHES MODIFIED="2015-07-21 16:41:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>We searched the Cochrane Kidney and Transplant Specialised Register up to 13 July 2015 through contact with the Trials Search Co-ordinator using search terms relevant to this review. The Cochrane Kidney and Transplant's Specialised Register contains studies identified from several sources the following sources.</P>
<OL>
<LI>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of kidney-related journals and the proceedings of major kidney conferences</LI>
<LI>Searching of the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected kidney and transplant journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</LI>
</OL>
<P>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Kidney and Transplant</A>.</P>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used in strategies for this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Reference lists of clinical practice guidelines, review articles and relevant studies were also searched.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY_SELECTION MODIFIED="2014-01-07 14:28:18 +1100" MODIFIED_BY="[Empty name]">
<P>The search strategy described was used to obtain titles and abstracts of studies that might be relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable. However studies and reviews that might have included relevant data or information on studies were retained initially. Three authors independently assessed retrieved abstracts and, if necessary the full text, of these studies to determine which studies satisfied the inclusion criteria. </P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Data extraction was carried out independently by three authors using standard data extraction forms. Studies reported in non-English language journals were translated before assessment. When more than one publication of one study was identified, reports were grouped together and the publication with the most complete data was used in the analyses. Where relevant outcomes were only published in earlier versions these data were used. Any discrepancy between published versions was highlighted. Where necessary, authors were contacted for additional information about their studies. Disagreements were resolved by discussion.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-07-21 16:17:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>The following items were used assessed using the risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study?</LI>
<UL>
<LI>Participants and personnel (performance bias)</LI>
<LI>Outcome assessors (detection bias)</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-07-21 15:56:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>For dichotomous outcomes (number with any kidney disease) results were expressed as risk ratio (RR) with 95% confidence intervals (CI). For continuous outcomes (severity or duration of haematuria or proteinuria, creatinine, GFR), the mean difference (MD) with 95% CI were calculated. Where possible the risk difference (RD) with 95% CI was calculated for each adverse effect. Otherwise any adverse effects were listed in the text for each intervention.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-07-21 15:57:46 +1000" MODIFIED_BY="Narelle S Willis">
<P>We planned to include data from the first part of any cross-over study if the data could be separated. However no cross-over studies were identified.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-07-21 17:00:42 +1000" MODIFIED_BY="Narelle S Willis">
<P>Any further information required from the original author was requested by written correspondence and any relevant information obtained was included in the review. We aimed to analyse available data in meta-analyses using the intention-to-treat (ITT) data. However where ITT data were only available graphically or were not provided and additional information could not be obtained from the authors, available data were used in analyses. Attrition rates, for example drop-outs, losses to follow-up and withdrawals were assessed.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-04-08 17:58:48 +1000" MODIFIED_BY="Narelle S Willis">
<P>Heterogeneity was analysed using a chi squared test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-12-19 14:45:06 +1100" MODIFIED_BY="Elisabeth M Hodson">
<P>We planned to assess for reporting bias using funnel plots. However we did not identify sufficient studies on any intervention to allow this assessment.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-12-19 14:45:45 +1100" MODIFIED_BY="[Empty name]">
<P>We pooled data using the random effects model but we also analysed the fixed effect model to ensure robustness of the model chosen.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-01-07 14:55:47 +1100" MODIFIED_BY="[Empty name]">
<P>We planned subgroup analyses to explore possible sources of heterogeneity among participants (severity of kidney disease, kidney pathology, age), interventions (agent, dose and duration of treatment) or associated with risk of bias might explain any observed heterogeneity of treatment effects. Examination of these possible between-study differences by subgroup analysis was not possible because of insufficient study data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-01-07 14:57:00 +1100" MODIFIED_BY="[Empty name]">
<P>Sensitivity analysis was undertaken where significant heterogeneity among studies existed and single studies appeared to be responsible for this heterogeneity. Where required results were reported with and without inclusion of such single studies.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY_DESCRIPTION MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<SEARCH_RESULTS MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>In our 2009 review (<LINK REF="REF-Chartapisak-2009" TYPE="REFERENCE">Chartapisak 2009</LINK>) a total of 909 reports were identified (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Of these, 13 reports underwent full text review. Ten studies (11 reports) were included (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Islek-1999" TYPE="STUDY">Islek 1999</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>; <LINK REF="STD-Peratoner-1990" TYPE="STUDY">Peratoner 1990</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>; <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>; and one three-armed study listed as two studies for analysis purposes <LINK REF="STD-Yoshimoto-1987a" TYPE="STUDY">Yoshimoto 1987a</LINK>; <LINK REF="STD-Yoshimoto-1987b" TYPE="STUDY">Yoshimoto 1987b</LINK>). Two studies were excluded (<LINK REF="STD-Hui_x002d_Lan-2001" TYPE="STUDY">Hui-Lan 2001</LINK>; <LINK REF="STD-Jin-2003" TYPE="STUDY">Jin 2003</LINK>).</P>
<P>In this review update, 37 new reports were identified. There were four reports of three new studies (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>; <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-Xu-2009" TYPE="STUDY">Xu 2009</LINK>) and 10 reports of five already included studies (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>; <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>). Sixteen additional studies (17 reports) were excluded.</P>
<P>Further information from the original authors was requested by written correspondence to five authors from whom additional trial information was obtained from three authors (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>).</P>
<P>Prior to publication a final search of the Specialised Register identified four new potential studies and these will be assessed for inclusion in a future update of this review (<LINK REF="STD-Ding-2014" TYPE="STUDY">Ding 2014</LINK>; <LINK REF="STD-NCT00301613" TYPE="STUDY">NCT00301613</LINK>; <LINK REF="STD-Wu-2013b" TYPE="STUDY">Wu 2013b</LINK>; <LINK REF="STD-Wu-2014c" TYPE="STUDY">Wu 2014c</LINK>). </P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>In this update 13 studies (26 reports) enrolling 1403 participants were included (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>; <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Islek-1999" TYPE="STUDY">Islek 1999</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>; <LINK REF="STD-Peratoner-1990" TYPE="STUDY">Peratoner 1990</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>; <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>; <LINK REF="STD-Xu-2009" TYPE="STUDY">Xu 2009</LINK>; <LINK REF="STD-Yoshimoto-1987a" TYPE="STUDY">Yoshimoto 1987a</LINK>; <LINK REF="STD-Yoshimoto-1987b" TYPE="STUDY">Yoshimoto 1987b</LINK>). One study (<LINK REF="STD-Yoshimoto-1987a" TYPE="STUDY">Yoshimoto 1987a</LINK>; <LINK REF="STD-Yoshimoto-1987b" TYPE="STUDY">Yoshimoto 1987b</LINK>) compared two different interventions with a single control intervention and was treated as two studies for the analyses. Four studies were available in abstract form only (<LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-Islek-1999" TYPE="STUDY">Islek 1999</LINK>; <LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK>; <LINK REF="STD-Yoshimoto-1987a" TYPE="STUDY">Yoshimoto 1987a</LINK>; <LINK REF="STD-Yoshimoto-1987b" TYPE="STUDY">Yoshimoto 1987b</LINK>). Twelve studies were published in English; one study published in Chinese was translated before assessment.</P>
<P>Five studies (856 enrolled participants) examined the effects of short-duration corticosteroids (14 to 28 days) on preventing persistent HSP-associated kidney disease at six to 12 months after presentation in comparison with placebo (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>) or supportive treatment (<LINK REF="STD-Islek-1999" TYPE="STUDY">Islek 1999</LINK>; <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>). Three studies included children with kidney disease at randomisation (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>). Children considered to have established HSP-associated kidney disease (proteinuria &gt; 300 mg/L or haematuria &gt; 10 red cells/high power field) were excluded from <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK> while <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK> and <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK> included children with any degree of kidney disease at randomisation. <LINK REF="STD-Islek-1999" TYPE="STUDY">Islek 1999</LINK> and <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK> only included children with no haematuria or proteinuria at presentation.</P>
<P>
<LINK REF="STD-Peratoner-1990" TYPE="STUDY">Peratoner 1990</LINK>, <LINK REF="STD-Yoshimoto-1987a" TYPE="STUDY">Yoshimoto 1987a</LINK> and <LINK REF="STD-Yoshimoto-1987b" TYPE="STUDY">Yoshimoto 1987b</LINK> (129 children) evaluated antiplatelet agents (dipyridamole, cyproheptadine and salicylates) in comparison with supportive treatment and <LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK> (228 children) compared heparin with placebo. <LINK REF="STD-Peratoner-1990" TYPE="STUDY">Peratoner 1990</LINK> provided outcome data separately for children with and without kidney disease at presentation while the other studies only included children without kidney disease at randomisation.</P>
<P>Five studies examined the treatment of severe HSP-associated kidney disease (nephrotic range proteinuria, International Study of Kidney Disease in Children grade II-IV changes on biopsy); <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK> (56 children) compared cyclophosphamide with no specific treatment and <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK> (19 children) compared cyclosporin with methylprednisolone. The <LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK> evaluated 54 adults with severe biopsy proven HSP kidney disease including proliferative GN and compared cyclophosphamide and prednisone to prednisone only. <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK> (15 children) compared azathioprine with mycophenolate mofetil with both treatment groups receiving prednisone. <LINK REF="STD-Xu-2009" TYPE="STUDY">Xu 2009</LINK> evaluated fosinopril compared with supportive treatment in 48 children.</P>
<P>Outcomes were assessed at six to 12 months in eight studies (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>; <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>; <LINK REF="STD-Peratoner-1990" TYPE="STUDY">Peratoner 1990</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>) and at two years in one study (<LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>). <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK> reported the outcomes at the end of the study without providing detailed information of the duration of the study. <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK> provided a further long-term outcome at eight years. The remaining four studies did not specify the timing of the outcome assessment (<LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK>; <LINK REF="STD-Islek-1999" TYPE="STUDY">Islek 1999</LINK>; <LINK REF="STD-Xu-2009" TYPE="STUDY">Xu 2009</LINK>; <LINK REF="STD-Yoshimoto-1987a" TYPE="STUDY">Yoshimoto 1987a</LINK>; <LINK REF="STD-Yoshimoto-1987b" TYPE="STUDY">Yoshimoto 1987b</LINK>).</P>
<P>Definitions for significant haematuria were provided in five studies (<LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>; <LINK REF="STD-Peratoner-1990" TYPE="STUDY">Peratoner 1990</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>; <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>). <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK> regarded any degree of haematuria on dipstick as significant and the other studies did not report a definition of haematuria. Definitions for significant proteinuria using urinary protein:creatinine (UPC) ratio, timed urine specimens or dipstick results were specified in seven studies (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>, <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>). The remaining studies did not provide a definition of significant proteinuria. See <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>
<I>.</I>
</P>
<P>Among the eight studies evaluating interventions to prevent persistent HSP-associated kidney disease, <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK> used UPC ratio as the primary end point while in the remaining studies the primary end point of kidney disease was defined by a composite of haematuria and proteinuria. In the two studies evaluating interventions for severe HSP-associated kidney disease, the primary end point was defined by a composite of proteinuria and reduced kidney function (<LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>), while <LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK> used a Birmingham Vascular Activity Score (BVAS) of zero at six months as indicating complete disease remission. The primary end point in the study comparing MMF with azathioprine was remission of proteinuria (<LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>). <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK> reported data on included randomised and non-randomised patients. Using information obtained from the authors, only randomised patients were included in the study analyses.</P>
<P>The primary outcome in <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK> was UPC ratio at 12 months but of the 296 children who had a 12 month follow-up visit, results of UPC ratio were only available in 247 children. Data on the number of children with haematuria or proteinuria were used in analyses at one and three months. At these time points, the number of children with available data was less than the number undergoing follow-up at that point.</P>
<P>No studies examining warfarin, ACEi or ARB, fish oil, immunoglobulin G, plasma exchange, antibody therapy or dapsone were identified.<BR/>
</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Eighteen studies (20 reports) were excluded. Three studies were not randomised, one study was enrolled the wrong population and 14 studies evaluated interventions not relevant to this review.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> describe the graphical representation of the risk of bias assessment for all studies.</P>
<ALLOCATION MODIFIED="2015-07-21 15:59:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>Six studies (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>; <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>) were determined to be at low risk of bias for random sequence generation and the risk of bias was unclear in the remaining studies.</P>
<P>Seven studies (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>; <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK> <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>; <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>) were determined to be a low risk of bias for allocation concealment, one study was at high risk of bias (<LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>), and the remaining studies had unclear risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2015-07-21 16:00:15 +1000" MODIFIED_BY="Narelle S Willis">
<P>Performance and detection bias was low in three studies (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>). In one study participants in both treatment groups received intravenous medications but it was not clear whether the investigators were blinded (<LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK>). Blinding of outcome assessors was reported in three studies (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>). <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK> was an open-label study and blinding was not reported in the remaining studies. Since the outcome measure of urinalysis reported by participants or investigators is a subjective outcome measure, it could be influenced by lack of blinding so these studies were considered to be at high risk of bias (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Xu-2009" TYPE="STUDY">Xu 2009</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-07-21 10:18:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>Four studies were considered to be at low risk of attrition bias (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>; <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Xu-2009" TYPE="STUDY">Xu 2009</LINK>). In two studies (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>) reporting of outcome data was considered at high risk of bias because of loss to follow-up or exclusion of data from the analyses. In the remaining studies insufficient information was provided to determine whether all patients entering the study were included in the analysis so the risk of bias was unclear.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Reporting included all important kidney outcomes and adverse effects of medications in nine studies (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>, <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>; <LINK REF="STD-Peratoner-1990" TYPE="STUDY">Peratoner 1990</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>). One study was considered at high risk of reporting bias as data on treatment outcomes was only available in graphical form (<LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>). In the remaining studies it was unclear whether important kidney outcomes including nephrotic syndrome, reduced kidney function and adverse effects of medications had not occurred or had not been reported.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Four studies appeared free of other potential sources of bias (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>; <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>). One author in <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK> was a <U>consult</U> for a pharmaceutical company and <LINK REF="STD-Islek-1999" TYPE="STUDY">Islek 1999</LINK> was an abstract-only publication with no full-text report identified and these two studies were judged to be at high risk of bias. In the remaining studies there was insufficient information provided to determine if there were other potential sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Preventing persistent kidney disease</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Prednisone versus placebo or supportive treatment</HEADING>
<P>In children with newly diagnosed HSP and without significant kidney disease, there was no significant difference in the risk of any kidney disease following prednisone treatment compared with placebo or supportive treatment (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (5 studies, 746 children): RR 0.73, 95% CI 0.43 to 1.24; I<SUP>2</SUP> = 44%).</P>
<P>There was no significant difference in the risk of development or persistence of kidney disease with prednisone compared with placebo or supportive treatment at one (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.1 (4 studies, 655 participants): RR 0.80, 95% CI 0.34 to 1.84; I<SUP>2</SUP> = 72%), three (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.2 (4 studies, 655 participants): RR 0.83, 95% CI 0.46 to 1.52; I<SUP>2</SUP> = 44%), six (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.3 (3 studies, 379 participants): RR 0.51, 95% CI 0.24 to 1.11; I<SUP>2</SUP> = 0%) and 12 months (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.4 (3 studies, 455 participants): RR 1.06, 95% CI 0.38 to 2.91; I<SUP>2</SUP> = 32%). There was substantial heterogeneity in study outcomes at one, three and 12 months, which was largely due to <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>. This study, which was at high risk of bias due to inadequate allocation concealment, showed a large benefit of prednisone in contrast to the other three studies. Sensitivity analysis with exclusion of this study eliminated the heterogeneity except at one month with no change to significance (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>In <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK> post hoc subgroup analysis of 71 children with kidney disease at or within one month of randomisation found that kidney disease was significantly less common at six months after prednisone therapy compared with placebo (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>.3: RR 0.45, 95% CI 0.21 to 0.98).</P>
<P>Two studies (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>) reported the number of children, who developed severe kidney disease with nephrotic range proteinuria, hypertension or reduced kidney function. Again there was no significant difference in the risk of severe kidney disease between children treated with prednisone or placebo (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; (2 studies, 418 children): RR 1.58, 95% CI 0.42 to 6.00; I<SUP>2</SUP> = 0%).</P>
<P>
<LINK REF="STD-Islek-1999" TYPE="STUDY">Islek 1999</LINK> assessed the duration of haematuria and proteinuria and found no significant difference in the duration of haematuria (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>.1 (33 children); MD -1.00, 95% CI -10.26 to 8.26) or proteinuria (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>.2 (33 children): MD -1.60, 95% CI -15.62 to 12.42).</P>
<P>The risk of gastrointestinal involvement requiring hospital admission was not significantly different between prednisone and placebo or supportive treatment (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK> (3 studies, 517 participants): RR 0.56, 95% CI 0.25 to 1.23; I<SUP>2</SUP> = 0%). In <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>, two children in the placebo group required surgery for intussusception and were withdrawn from the study. Based on patient diary records in <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>, children on prednisone had a significantly lower pain severity score for abdominal or joint pain and had significantly shorter durations of abdominal pain but not joint pain compared with placebo.</P>
<P>
<LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK> completed an eight-year follow-up on 138/176 patients originally randomised. They reported minor abnormalities after two clinical screenings in 10 patients; eight who had received prednisone and two who received placebo. There was no significant differences in haematuria <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.1: RR 4.86, 95% CI 0.24 to 99.39), proteinuria (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.2: RR 2.92, 95% CI 0.12 to 70.35), haematuria and proteinuria (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.3: RR 2.92, 95% CI 0.12 to 70.35), hypertension (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.4: RR 0.97, 95% CI 0.14 to 6.70), and decreased GFR by Schwartz formula (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>.5: RR 4.86, 95% CI 0.24 to 99.39).</P>
<P>
<LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK> and <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK> reported there were no serious adverse effects caused by prednisone or placebo. In <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>, children receiving prednisone had a 1 kg greater increase in weight and 4 mm Hg increase in diastolic blood pressure during treatment. In <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>, one child developed behavioural problems and one had an infection, these were considered related to prednisone therapy, while one child developed abdominal pain in the placebo group. Adverse effects were not recorded in <LINK REF="STD-Islek-1999" TYPE="STUDY">Islek 1999</LINK> or <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antiplatelet agents versus supportive treatment</HEADING>
<P>In children treated with antiplatelet agents compared with support treatment only, there was no significant difference in the risk of kidney disease occurring at any time during follow-up in children without kidney disease at entry (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.1 (2 studies, 101 children): RR 1.16, 95% CI 0.46 to 2.95; I<SUP>2</SUP> = 0%). <LINK REF="STD-Peratoner-1990" TYPE="STUDY">Peratoner 1990</LINK> reported no significant difference in kidney disease persisting in children with kidney disease at entry (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.2 (19 children): RR 0.92, 95% CI 0.23 to 3.72).</P>
<P>
<LINK REF="STD-Yoshimoto-1987a" TYPE="STUDY">Yoshimoto 1987a</LINK> reported no significant difference in the risk of kidney disease with aspirin compared with supportive treatment only (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> (18 children): RR 0.14, 95% CI 0.01 to 2.42).</P>
<P>Duration of follow-up and adverse effects were not recorded in these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Heparin versus placebo</HEADING>
<P>
<LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK> reported IV heparin significantly reduced kidney disease (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> (228 children): RR 0.27, 95% CI 0.14 to 0.55), in haematuria (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>.1 (22 children): RR 0.15, 95% CI 0.03 to 0.67) and in proteinuria (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>.2 (228 children): RR 0.37, 95% CI 0.15 to 0.91) at three months or longer after the onset or relapse of HSP compared to placebo. The risk for nephrotic syndrome did not differ significantly between the groups but event numbers were small resulting in wide confidence intervals (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>.3 (228 children): RR 0.31, 95% CI 0.03 to 2.89). The development of kidney disease was significantly delayed in the heparin group compared with placebo (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK> (228 children): MD 47.3 days, 95% CI 34.24 to 60.36). No child developed severe bleeding.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treating severe kidney disease</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Cyclophosphamide versus supportive treatment</HEADING>
<P>In a single study of children (<LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>) with significant HSP-associated kidney disease (proteinuria, reduced kidney function, crescents, segmental lesions or both on kidney biopsy) treated within three months of onset of HSP, there was no significant difference in the risk for persistent kidney disease of any severity (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> (56 children): RR 1.07, 95% CI 0.65 to 1.78), severe kidney disease (heavy proteinuria, reduced GFR, ESKD) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK> (56 children): RR 0.88, 95% CI 0.37 to 2.09) or ESKD (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK> (56 children): RR 0.75, 95% CI 0.18 to 3.05) during follow-up between patients treated with cyclophosphamide and those given supportive treatment. Adverse effects of cyclophosphamide were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cyclophosphamide plus steroids versus steroids</HEADING>
<P>
<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK> compared cyclophosphamide and methylprednisolone followed by prednisone with methylprednisolone and prednisone in adults. There was no significant difference in the number of patients, who achieved a BVAS of zero by six months (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.1 (54 participants): RR 1.16, 95% CI, 0.26 to 5.24) or in the number of patients whose BVAS score improved by six months (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.2 (54 participants): RR 0.98, 95% CI 0.81 to 1.19). No significant differences were reported in the secondary outcomes including hypertension, reduced GFR, proteinuria, improvement in renal function and ESKD at 12 months (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). Mortality was higher in the prednisone treated group, however this was not significant (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>.7 (54 participants): RR 0.19, 95% CI 0.02 to 1.50). These deaths were not considered to be related to the treatments received and the authors noted that patients in the prednisone group had significantly more severe disease at baseline based on BVAS scores. There were no significant differences in adverse effects (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cyclosporin versus methylprednisolone</HEADING>
<P>
<LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK> compared cyclosporin with methylprednisolone in children with severe kidney disease. All seven children treated with cyclosporin compared with four of eight treated with methylprednisolone were in remission by three months but the difference was not significant (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK> (15 children): RR 1.88, 95% CI 0.95 to 3.69) due to small patient numbers. At the two-year follow-up, 23 patients were assessed including 8 non-randomised patients; remission rate was 70% in children treated with cyclosporin and 58% in children treated with methylprednisolone. At final follow-up at a mean of 6.3 years, 6/7 children treated with cyclosporin compared with 5/8 treated with methylprednisolone were in remission, however the difference was not significant (<LINK REF="CMP-006.02" TYPE="ANALYSIS">Analysis 6.2</LINK> (15 children): RR 1.37, 95% CI 0.74,2.54). Adverse effects related to cyclosporin and methylprednisolone were not reported separately for the randomised patients.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Azathioprine plus prednisone versus mycophenolate mofetil plus prednisone</HEADING>
<P>
<LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK> compared azathioprine plus prednisone versus mycophenolate mofetil plus prednisone in children with biopsy proven HSPN (Class I-III). There was no significant difference in protein remission between the two groups (<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK> (17 children): RR 1.32, 95% CI 0.86 to 2.02). There was no significant difference in the number of children with improvement in kidney histology between treatment groups (<LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK> (17 children): RR 1.24,95% CI 0.66 to 2.36).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fosinopril plus supportive treatment versus supportive treatment alone</HEADING>
<P>
<LINK REF="STD-Xu-2009" TYPE="STUDY">Xu 2009</LINK> reported fosinopril given for two months significantly increased the number of children with complete remission of proteinuria compared with supportive treatment (<LINK REF="CMP-008.01" TYPE="ANALYSIS">Analysis 8.1</LINK> (48 children): RR 5.83, 95% CI 1.50 to 22.74).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other outcomes</HEADING>
<P>In most studies the severity of haematuria and proteinuria, the degree of kidney dysfunction and the presence of hypertension were not specified. <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK> provided information on UPC ratios and <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK> provided separate information on ESKD.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>
<BR/>
</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-07-21 17:03:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>We identified 13 studies of which eight examined the efficacy of therapies to prevent persistent kidney disease in HSP and five examined therapies to treat established severe kidney disease.</P>
<SUBSECTION>
<HEADING LEVEL="4">Prevention of persistent kidney disease - prednisone</HEADING>
<P>A meta-analysis of five studies showed no evidence of benefit of prednisone over placebo or no treatment in preventing persistent kidney disease in children with none or minor kidney disease at presentation. Thus there is now considerable evidence that the use of steroid therapy at presentation of HSP is not indicated for the prevention of persistent kidney disease as determined by the presence of abnormal UPC ratio or persistent or new abnormalities on urinalysis. Data overall and at specified time points after presentation revealed no significant difference in the number of children with persistent kidney disease. Eight-year follow-up in one study found no significant differences in the numbers with urinary abnormalities or hypertension.</P>
<P>Only two studies assessed the use of prednisone in patients with severe kidney disease (nephrotic syndrome, nephritic syndrome, reduced kidney function) and identified no evidence of benefit. Because of small numbers of events resulting in wide confidence intervals and inadequate definition of severe disease, there remains uncertainty as to the efficacy of prednisone in preventing severe HSP-associated kidney disease</P>
<P>The lack of significant differences between prednisone and placebo or supportive treatment in the numbers with kidney disease at one, three and six months suggests that prednisone did not result in more rapid resolution of kidney disease overall. However <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK> presented a post hoc analysis of 71 children, who had kidney disease at or within one month of presentation. Prednisone therapy for 28 days significantly reduced the number of children with persistent kidney disease at six months. The study was not stratified before randomisation for the presence or absence of kidney disease and the sample size was small so the results can only be considered as hypothesis-generating. The study only provided outcome data to six months after randomisation so it is unclear whether prednisone treatment reduced the number of patients with persistent HSP-associated kidney disease overall or promoted more rapid resolution of kidney disease compared with placebo. In addition, children considered to have established kidney disease at randomisation were not included in this study. In the other two well-designed studies (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>) of prednisone therapy, children with any severity of kidney disease at presentation were potentially included and a meta-analysis of these studies showed no significant difference in the risk for persistent HSPN at 12 months.</P>
<P>Two studies found no significant difference in the number of children with abdominal complications of HSP (<LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>). However <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>) reported that the severity and duration of abdominal pain as well as the duration of joint pain were significantly less severe in children treated with prednisone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Prevention of persistent kidney disease - antiplatelet agents and heparin</HEADING>
<P>No evidence of benefit of antiplatelet agents (dipyridamole, cyproheptadine, salicylates) was demonstrated in two small studies suggesting that these agents have no role in preventing kidney disease in HSP. One study (<LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK>), available in abstract form only, demonstrated that heparin reduced the number of children with kidney disease. Heparin or placebo were administered to children at onset of disease and at relapse and it was not possible to determine how many children in each group received more than one period of treatment. Though bleeding was not reported in this study, the use of such a potentially dangerous therapy is not justified when only about a third of children with HSP develop kidney disease and less than 2% develop severe kidney disease (nephrotic syndrome, nephritic syndrome, kidney failure) (<LINK REF="REF-Narchi-2005" TYPE="REFERENCE">Narchi 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment of severe kidney disease</HEADING>
<P>Two studies evaluated cyclophosphamide in children and adults with HSPN and nephrotic range proteinuria. <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK> reported no evidence of benefit of cyclophosphamide alone compared with no specific therapy. <LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK> is the first study in adults with severe HSPN; they observed no evidence of benefit with the addition of cyclophosphamide to prednisone. There were no significant differences in the adverse events between the two groups.</P>
<P>While preliminary data in <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK> suggested that cyclosporin may be more effective than methylprednisolone and prednisone in inducing remission in children with HSP and nephrotic range proteinuria, long-term follow-up at a mean of 6.3 years showed no statistical difference in the remission rates between cyclosporin and methylprednisolone groups. However study numbers were very small limiting the value of this study.</P>
<P>
<LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK> compared azathioprine and mycophenolate mofetil therapy in children with severe kidney disease and reported the number with remission of proteinuria did not differ significantly between treatment groups but there was considerable imprecision because of small patient numbers.</P>
<P>
<LINK REF="STD-Xu-2009" TYPE="STUDY">Xu 2009</LINK> compared fosinopril with supportive treatment and reported the number achieving complete remission of proteinuria was higher in the fosinopril group.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Thirteen studies enrolling 1403 participants were included in this review update; four studies only available in the abstract form and several studies included small numbers of patients with incomplete outcome data. Incomplete reporting of these studies may result in incomplete information being included in this systematic review.</P>
<P>Three well-designed, placebo controlled studies (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>; <LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>) have provided data in over 400 children that there is no significant benefit of prednisone therapy at six to 12 months in children with no or minor kidney involvement at presentation. In addition, eight year follow-up data in <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK> found no longer term benefit. Therefore further RCTs to evaluate prednisone to prevent kidney disease in this group of children presenting with HSP are unlikely to be justified.</P>
<P>Based on observational studies (<LINK REF="REF-Niaudet-1998" TYPE="REFERENCE">Niaudet 1998</LINK>), intravenous methylprednisolone followed by oral prednisone is commonly used in patients with nephrotic range proteinuria and no reduction in kidney function. However there are no RCTs evaluating methylprednisolone and prednisone compared with placebo or no treatment in patients with nephrotic range proteinuria and normal kidney function at or soon after presentation. Because of the known risk of permanent kidney damage and reduced kidney function, it is unlikely that investigators would be prepared to enrol their patients if such a study was proposed.</P>
<P>At present there are few RCTs with small patient numbers evaluating the treatment of HSPN with immunosuppressive medication to determine the benefits and harms of such treatment for patients with nephrotic syndrome with or without reduced kidney function and with or without more than 50% crescents on biopsy. Nevertheless immunosuppressive agents are commonly used in an attempt to treat established severe kidney disease in HSP with observational studies suggesting benefit of methylprednisolone (<LINK REF="REF-Niaudet-1998" TYPE="REFERENCE">Niaudet 1998</LINK>), azathioprine (<LINK REF="REF-Bergstein-1998" TYPE="REFERENCE">Bergstein 1998</LINK>), mycophenolate mofetil (<LINK REF="REF-Du-2012" TYPE="REFERENCE">Du 2012</LINK>), cyclophosphamide (<LINK REF="REF-Flynn-2001" TYPE="REFERENCE">Flynn 2001</LINK>; <LINK REF="REF-Iijima-1998" TYPE="REFERENCE">Iijima 1998</LINK>; <LINK REF="REF-Tanaka-2003" TYPE="REFERENCE">Tanaka 2003</LINK>) and cyclosporin (<LINK REF="REF-Ronkainen-2003" TYPE="REFERENCE">Ronkainen 2003</LINK>). However in the four RCTs included in this review, no significant benefits of cyclophosphamide, cyclosporin or mycophenolate mofetil were identified (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>; <LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>; <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>). Patient numbers in the studies of cyclosporin and mycophenolate were very small resulting in considerable imprecision of results so these treatment modalities need further study. Cyclophosphamide is recommended for patients with crescentic GN (<LINK REF="REF-KDIGO-2012" TYPE="REFERENCE">KDIGO 2012</LINK>). The lack of significant benefit of cyclophosphamide may be related to the types of patients included in the two studies. Although all children included in the <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK> study had crescentic GN, the delay between onset of disease and treatment (at least three months) may have allowed the development of chronic changes, which were not amenable to therapy. In addition treatment may have been more effective if methylprednisolone and then oral high dose prednisone had been administered also. In the <LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK> only 30% of participants had crescentic disease, which may have influenced why there was no significant additional benefit of cyclophosphamide over methylprednisolone and prednisone alone. However while these issues might suggest that further studies of cyclophosphamide in patients with crescentic GN associated with HSP are indicated, the potential long term adverse effects of cyclophosphamide particularly in children (<LINK REF="REF-Coutinho-2001" TYPE="REFERENCE">Coutinho 2001</LINK>) mean that such studies are unlikely to be performed.</P>
<P>Adverse events of therapies were not all well reported. Limited reporting revealed small numbers of adverse events in all studies with no significant difference between interventions. No studies were identified which evaluated therapy to prevent or treat persistent kidney disease in participants with recurrent episodes of HSP.</P>
<P>In the studies evaluating prednisone therapy, the outcomes reported were poorly defined except for one study (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>), which used UPC ratio as the primary outcome. The potential significance for long-term kidney function of any residual urinary abnormalities could not be assessed in the other studies, since they reported the end point as the presence of haematuria or proteinuria or both without measuring the degree of proteinuria.</P>
<P>No RCTs were identified which examined intravenous immunoglobulin, rituximab or plasma exchange. No studies examining fish oil, ACEi or ARB were identified. No studies specifically addressing whether therapy reduced the risk of recurrent episodes of HSP were identified.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Sequence generation and allocation concealment were at low risk of bias in six (50%) and seven (58%) respectively. This may be attributed to poorer reporting of these parameters in the earlier studies. Blinding of participants, investigators and outcome assessors was only reported in three studies, reflecting a high risk of bias in the remaining studies since knowledge of treatment groups could influence patient management and reporting. Only five studies were at low risk of attrition bias. The otherwise robust study of <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>, was at high risk of attrition bias due to a significant drop out rate with only 72% (123/171) reporting the primary outcome. Eight studies were at low risk of reporting bias. Studies with a high risk of bias are associated with an increased likelihood of results favouring the study intervention (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>). Exclusion of the study with a high risk of bias removed heterogeneity between studies without altering the overall result, reinforcing the strength of the evidence suggesting that short courses of prednisone do not prevent serious kidney disease in children with HSP.</P>
<P>Only the five studies comparing prednisone with placebo or supportive treatment for the prevention of persistent kidney disease in HSP could be assessed in a summary of findings table (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The overall quality of the studies was considered moderate for persistence of kidney disease at any time after treatment and for the number of children with continuing kidney disease at varying time points. With the removal of one study, which had inadequate allocation concealment and no blinding, the remaining three studies were graded as of high quality at the three month interval but only moderate at 12 months because of the small number of events and high loss to follow-up in <LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>. The number developing severe kidney disease was graded as low in two studies, as a result of significant loss to follow-up in the largest included study and small numbers of events.</P>
<P>The remaining eight studies could not be included into summary of findings tables as they were single studies with small numbers or data could not be included in meta-analyses.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>A thorough search utilising Cochrane Kidney and Transplant's Specialised Register was completed in July 2015.</P>
<P>The Specialised Register includes published studies and conference abstracts with no restriction of language. The omission of eligible studies was therefore minimised, although potentially eligible studies identified prior to publication have yet to be included (<LINK REF="STD-Ding-2014" TYPE="STUDY">Ding 2014</LINK>; <LINK REF="STD-NCT00301613" TYPE="STUDY">NCT00301613</LINK>; <LINK REF="STD-Wu-2013b" TYPE="STUDY">Wu 2013b</LINK>; <LINK REF="STD-Wu-2014c" TYPE="STUDY">Wu 2014c</LINK>). However 40% of study reports in the Specialised Register have been identified by handsearching of conference proceedings so it remains possible that further studies of therapy to prevent or treat serious kidney disease in HSP will be identified as conference proceedings from different congresses are searched.</P>
<P>Four (33%) of the included studies were only available in the abstract form, thus limiting information on study methods and outcomes. Four of the studies were published prior to 2000 before the CONSORT checklist (first published in 1996) would influence trial methodology and reporting. Incomplete reporting of these studies may result in incomplete information being included in this systematic review.</P>
<P>Two authors independently undertook all the steps of this review thereby minimising risks of errors in determining study eligibility, data extraction and risk of bias assessment and data synthesis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-07-21 16:56:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>Three systematic reviews have previously assessed the effects of corticosteroid therapy to prevent or alter the course of kidney disease in HSP (<LINK REF="REF-Weiss-2007" TYPE="REFERENCE">Weiss 2007</LINK>; <LINK REF="REF-Wyatt-2001" TYPE="REFERENCE">Wyatt 2001</LINK>; <LINK REF="REF-Zaffanello-2007" TYPE="REFERENCE">Zaffanello 2007</LINK>). All three included data from RCTs and observational studies. Conclusions based on non-randomised study designs are more likely to be biased towards a benefit of treatment (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>). Two reviews determined that it remained unclear whether corticosteroid therapy prevented or altered the course of HSP-associated kidney disease (<LINK REF="REF-Wyatt-2001" TYPE="REFERENCE">Wyatt 2001</LINK>; <LINK REF="REF-Zaffanello-2007" TYPE="REFERENCE">Zaffanello 2007</LINK>). The third review concluded that corticosteroids decreased the likelihood of developing persistent kidney disease but did not prevent kidney disease (<LINK REF="REF-Weiss-2007" TYPE="REFERENCE">Weiss 2007</LINK>). This conclusion was based on a meta-analysis of the ad hoc subgroup of children with kidney abnormalities within one month of presentation from <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK> combined with data from two other studies (<LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>; <LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>). With the inclusion in this review of another large study (<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>), which showed no significant benefit of corticosteroid therapy, the evidence base from RCTs supports the conclusion that corticosteroids given at initial presentation of HSP do not prevent the development or persistence of kidney disease in HSP.</P>
<P>One review also evaluated immunosuppressive and other therapies in HSP (<LINK REF="REF-Zaffanello-2007" TYPE="REFERENCE">Zaffanello 2007</LINK>). It concluded based on observational studies that cyclophosphamide was of value in treating HSP-associated kidney disease. The two studies evaluating cyclophosphamide in this review did not show any benefit of cyclophosphamide (<LINK REF="STD-CESAR-Study-2010" TYPE="STUDY">CESAR Study 2010</LINK>, <LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>).The studies comparing cyclosporin with methylprednisolone and MMF with azathioprine were too small to establish whether or not these treatments were effective (<LINK REF="STD-Fuentes-2010" TYPE="STUDY">Fuentes 2010</LINK>; <LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>).</P>
<P>The KDIGO guidelines (<LINK REF="REF-KDIGO-2012" TYPE="REFERENCE">KDIGO 2012</LINK>) on HSP recommend treatment with ACEi or ARB in patients with HSPN and persistent low grade proteinuria and recommend corticosteroids after a trial of ACEi or ARB in patients with larger amounts of proteinuria as in patients with IgA nephropathy. However these recommendations have been challenged on the basis that the natural history of HSPN is different from IgA nephropathy with the risk of early severe inflammatory episodes with glomerular crescents followed by a rapid evolution to glomerulosclerosis. Thus delayed treatment may increase the risk of CKD progression so early treatment with methylprednisolone pulses with immunosuppressive drugs, plasma exchange or both is commonly commenced based on observational data. However currently there are no data from RCTs to support or refute this alternative management (<LINK REF="REF-Davin-2013" TYPE="REFERENCE">Davin 2013</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-07-21 16:12:49 +1000" MODIFIED_BY="Narelle S Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2015-07-21 10:07:03 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Prevention of kidney disease in HSP</HEADING>
<UL>
<LI>No evidence of benefit has been identified from RCTs for the use of prednisone to prevent serious kidney disease in children with HSP with or without minor kidney abnormalities at presentation.</LI>
<LI>Small studies examining antiplatelet agents have not demonstrated any benefit in preventing serious kidney disease but the quality of evidence is low.</LI>
<LI>In a single study heparin reduced the risk for kidney disease but the quality of evidence is low and the use of such a potentially harmful treatment cannot be justified when only a third of children with HSP develop kidney disease and most resolve spontaneously.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment of serious kidney disease in HSP</HEADING>
<UL>
<LI>No evidence of benefit has been found for treatment with cyclophosphamide treatment in children and adults with HSP and severe kidney disease.</LI>
<LI>It remains unclear whether cyclosporin is more effective than methylprednisolone in children with HSP and severe kidney disease and further studies with longer follow-up are required.</LI>
<LI>It remains unclear whether mycophenolate mofetil has a role in the treatment of severe kidney disease so larger studies with longer follow-up are required.</LI>
<LI>No studies addressing the management of kidney disease in participants with recurrent episodes of HSP were identified.</LI>
</UL>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-07-21 16:12:49 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Prevention of serious kidney disease</HEADING>
<UL>
<LI>While no evidence of benefit of short-term prednisone to prevent the development of HSPN has been identified, it remains possible that prednisone therapy has a role in children with risk factors for developing kidney disease including older age (<LINK REF="REF-Shin-2006" TYPE="REFERENCE">Shin 2006</LINK>), severe abdominal pain (<LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>; <LINK REF="REF-Shin-2006" TYPE="REFERENCE">Shin 2006</LINK>), persistent (<LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>; <LINK REF="REF-Shin-2006" TYPE="REFERENCE">Shin 2006</LINK>) or recurrent purpura (<LINK REF="REF-Shin-2006" TYPE="REFERENCE">Shin 2006</LINK>) so that a further RCT in this group of children might be warranted. However recruitment to a placebo controlled RCT may be difficult since <LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK> has demonstrated that short-course prednisone significantly reduces the severity and duration of abdominal pain in children with HSP making it unlikely that clinicians will be prepared to withhold prednisone from children with severe HSP-associated abdominal pain.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment of serious kidney disease in HSP</HEADING>
<UL>
<LI>Adequately powered well-designed RCTs with at least five year follow-up periods are particularly needed in children with HSP-associated nephritic syndrome, nephrotic syndrome or both.</LI>
<LI>The study treatment investigated should be adapted according to the severity of kidney disease and should be started early after the onset of HSPN (<LINK REF="REF-Davin--2011" TYPE="REFERENCE">Davin 2011</LINK>)</LI>
<LI>As suggested by <LINK REF="REF-Davin--2011" TYPE="REFERENCE">Davin 2011</LINK>, possible treatment regimens to be evaluated include:</LI>
<UL>
<LI>Methylprednisolone</LI>
<LI>Calcineurin inhibitors</LI>
<LI>Mycophenolate mofetil</LI>
<LI>Tonsillectomy</LI>
<LI>Plasma exchange alone or in combination with other therapies</LI>
<LI>Rituximab and other biologicals</LI>
</UL>
</UL>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-05-08 16:31:16 +1000" MODIFIED_BY="Ann Jones">
<UL>
<LI>We thank Dr Dudley, Dr Smith and Dr Tizard for additional information on their RCT. We thank Dr Ronkainen, Dr Nuutinen and Dr Mara Medeiros for additional information on their RCTs</LI>
<LI>We acknowledge the contributions made by authors Wattana Chartapisak and Sauwalak Opastrirakul to a previous version of this review</LI>
<LI>We would like to thank Drs Michael Dillon, Matti Nuutinen and Lesley Rees for their editorial advice during the preparation of this review</LI>
<LI>This work was presented in part at the 42nd Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology (Melbourne 2006)</LI>
<LI>We would like to thank Sunny Wu for translating one paper.</LI>
</UL>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-08-02 17:08:16 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Deirdre Hahn: nothing to declare</LI>
<LI>Elisabeth Hodson: nothing to declare</LI>
<LI>Narelle Willis: nothing to declare</LI>
<LI>Jonathan Craig: nothing to declare</LI>
</UL>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-07-21 16:34:23 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Wattana Chartapisak: study selection, quality appraisal, data extraction, data analysis, writing original protocol, writing original review.</LI>
<LI>Sauwalak Opastrirakul: study selection, quality appraisal, data extraction, writing original protocol</LI>
<LI>Elisabeth Hodson: study selection, quality appraisal, data extraction, data analysis, writing original protocol, writing original review, updating review.</LI>
<LI>Narelle Willis: reviewing protocol and review, data analysis</LI>
<LI>Jonathan Craig: writing review, disagreement resolution</LI>
<LI>Deirdre Hahn: study selection, quality appraisal, data extraction, data analysis, writing of manuscript for update of review</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-08-02 17:08:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>New methodology for assessing the risk of bias has replaced the quality assessment checklist. Studies of therapies with herbal treatments and non-pharmacological interventions were excluded.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<STUDIES MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<INCLUDED_STUDIES MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-CESAR-Study-2010" MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="CESAR Study 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E, CESAR study group</AU>
<TI>Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schonlein Purpura</TI>
<SO>Kidney International</SO>
<YR>2010</YR>
<VL>78</VL>
<NO>5</NO>
<PG>495-502</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20505654"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-09 17:04:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pillebout E, Alberti C, Guillevin L, Thervet E, CESAR Study Group</AU>
<TI>Prospective randomized study of cyclophosphamide and steroid versus steroid alone therapy in adult patients with severe Henoch Schonlein Purpura (HSP) [abstract no: SA275]</TI>
<SO>World Congress of Nephrology; 2009 May 22-26; Milan, Italy</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-07-13 09:24:39 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 09:24:39 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CTG" VALUE="NCT00190229"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dudley-2013" MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="Dudley 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-07-09 17:06:14 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dudley J, Smith G, Llewellyn-Edwards A, Tizard EJ</AU>
<TI>Randomised placebo controlled trial to assess the role of early prednisolone on the development and progression of Henoch-Schonlein Purpura Nephritis [abstract no: 270 (FC)]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>9</NO>
<PG>1457</PG>
<IDENTIFIERS MODIFIED="2015-07-09 17:06:14 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-07-09 17:06:14 +1000" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00691227"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dudley J, Smith G, Llewelyn-Edwards A, Bayliss K, Pike K, Tizard J</AU>
<TI>Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP)</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2013</YR>
<VL>98</VL>
<NO>10</NO>
<PG>756-63</PG>
<IDENTIFIERS MODIFIED="2015-07-09 17:08:46 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-07-09 17:08:46 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="23845696"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-09 17:07:03 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dudley J, Smith GC, Llewellyn-Edwards A, Tizard J</AU>
<TI>Randomised placebo controlled trial to assess the role of early prednisolone on the development and progression of Henoch-Schonlein Purpura nephritis [abstract no: SA-FC056]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Abstracts</NO>
<PG>47A</PG>
<IDENTIFIERS MODIFIED="2015-07-09 17:07:03 +1000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-07-13 09:25:02 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 09:25:02 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="ISRCTN" VALUE="ISRCTN71445600"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fuentes-2010" MODIFIED="2015-07-09 17:24:38 +1000" MODIFIED_BY="[Empty name]" NAME="Fuentes 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-09 17:24:38 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fuentes Y, Valverde S, Velasquez-Jones L, Romero B, Ramón G, Medeiros M</AU>
<TI>Comparison of azathioprine vs mofetil mycophenolate for Henoch-Schonlein nephritis treatment [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>9</NO>
<PG>1802</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2002" MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="He 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-07-21 15:43:21 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>He YY, Hongmei S, Lihua S, Min W</AU>
<TI>Preventive value of heparin on the occurrence of nephropathy in Henoch-Schoenlein Purpura: a randomized controlled clinical trial [abstract no: 0364]</TI>
<SO>23rd International Congress of Pediatrics; 2001 Sep 9 - 14; Beijing, China</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He YY, Pan W, Song HM, Wei M, Zhu CY</AU>
<TI>Preventive effect of heparin on the development of nephropathy in Henoch-Schoenlein purpura-a randomized controlled clinical trial</TI>
<SO>Chinese Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>40</VL>
<NO>2</NO>
<PG>99-102</PG>
<IDENTIFIERS MODIFIED="2015-07-09 17:29:27 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-07-09 17:29:27 +1000" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00415840"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huber-2004" MODIFIED="2015-07-13 09:24:21 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Huber 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-07-09 17:34:32 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huber AM, King J, McLaine P, Klassen T, Pothos M</AU>
<TI>A randomized, placebo-controlled trial of prednisone in early Henoch Schonlein purpura [ISRCTN85109383]</TI>
<SO>BMC Medicine</SO>
<YR>2004</YR>
<VL>2</VL>
<PG>7</PG>
<IDENTIFIERS MODIFIED="2015-07-09 17:34:12 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-07-09 17:34:12 +1000" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="15059282"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-07-13 09:24:21 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 09:24:21 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="ISRCTN" VALUE="85109383"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Islek-1999" MODIFIED="2014-01-30 12:26:48 +1100" MODIFIED_BY="Narelle S Willis" NAME="Islek 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-01-30 12:26:48 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Islek I, Sezer T, Totan M, Cakir M, Kucukoduk S</AU>
<TI>The effect of profilactic prednisolon therapy on renal involvement in henoch schonlein vasculitis</TI>
<SO>XXXVI Congress of the European Renal Association European Dialysis &amp; Transplant Association; 1999 Sep 5-8; Madrid (Spain)</SO>
<YR>1999</YR>
<PG>103</PG>
<IDENTIFIERS MODIFIED="2009-04-08 13:17:17 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 13:17:17 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00484464"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Jauhola-2010" MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="Jauhola 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-09 17:39:29 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jauhola O, Ronkainen J, Ala-Houhala M, Autio-Harmainen H, Holtta T, Jahnukainen T, et al</AU>
<TI>Cyclosporine A (CyA) versus MP pulses (MP) in severe Henoch-Schoenlein nephritis (HSN): outcome after 2 year follow-up [abstract no: O05]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>9</NO>
<PG>1584</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-09 17:41:31 +1000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, et al</AU>
<TI>Cyclosporine A vs. methylprednisolone for Henoch-Schonlein nephritis: a randomized trial</TI>
<SO>Pediatric Nephrology</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>12</NO>
<PG>2159-66</PG>
<IDENTIFIERS MODIFIED="2013-03-14 14:07:46 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-03-14 14:07:46 +1100" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE="21626222"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-13 09:33:56 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al</AU>
<TI>Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2010</YR>
<VL>95</VL>
<NO>11</NO>
<PG>871-6</PG>
<IDENTIFIERS MODIFIED="2015-07-13 09:33:53 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="20371584"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al</AU>
<TI>Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2010</YR>
<VL>95</VL>
<NO>11</NO>
<PG>877-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20852275"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-09 17:43:25 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ronkainen J, Ala-Houhala M, Antkainen M, Jahnukainen T, Koskimies O, Merenmies J, et al</AU>
<TI>Cyclosporine A (CyA) versus MP pulses (MP) in the treatment of severe Henoch-Schonlein Nephritis (HSN) [abstract no: COD. PP38]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>10</NO>
<PG>1531</PG>
<IDENTIFIERS MODIFIED="2015-07-09 17:43:25 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-07-09 17:43:25 +1000" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00689778"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-05-14 10:40:27 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-05-14 10:40:27 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CTG" VALUE="NCT00425724"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mollica-1992" MODIFIED="2015-07-09 17:35:36 +1000" MODIFIED_BY="[Empty name]" NAME="Mollica 1992" YEAR="1992">
<REFERENCE MODIFIED="2015-07-09 17:35:36 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mollica F, Li Volti S, Garozzo R, Russo G</AU>
<TI>Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura</TI>
<SO>European Journal of Pediatrics</SO>
<YR>1992</YR>
<VL>151</VL>
<NO>2</NO>
<PG>140-4</PG>
<IDENTIFIERS MODIFIED="2009-04-08 13:32:21 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 13:32:21 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1343079"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peratoner-1990" MODIFIED="2015-07-09 17:36:20 +1000" MODIFIED_BY="[Empty name]" NAME="Peratoner 1990" YEAR="1990">
<REFERENCE MODIFIED="2015-07-09 17:36:20 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peratoner L, Longo F, Lepore L, Freschi P</AU>
<TI>Prophylaxis and therapy of glomerulonephritis in the course of anaphylactoid purpura. The results of a polycentric clinical trial</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1990</YR>
<VL>79</VL>
<NO>10</NO>
<PG>976-7</PG>
<IDENTIFIERS MODIFIED="2009-04-08 13:33:33 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 13:33:33 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="2264475"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Ronkainen-2006a" MODIFIED="2015-07-13 09:34:47 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Ronkainen 2006a" YEAR="2006">
<REFERENCE MODIFIED="2015-07-13 09:34:47 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al</AU>
<TI>Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2010</YR>
<VL>95</VL>
<NO>11</NO>
<PG>871-6</PG>
<IDENTIFIERS MODIFIED="2015-07-13 09:34:44 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="20371584"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-08-15 15:13:22 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al</AU>
<TI>Outcome of Henoch-Schoenlein purpura 8 years after the treatment with placebo or prednisone at disease onset [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>9</NO>
<PG>1678</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-09 17:36:51 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al</AU>
<TI>Outcome of Henoch-Schonlein purpura 8 years after treatment with a placebo or prednisone at disease onset</TI>
<SO>Pediatric Nephrology</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>6</NO>
<PG>933-9</PG>
<IDENTIFIERS MODIFIED="2013-08-08 09:57:10 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="22311342"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-09 16:52:05 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al</AU>
<TI>Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2010</YR>
<VL>95</VL>
<NO>11</NO>
<PG>877-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20852275"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-08 13:35:06 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ronkainen J, Koskimies O, Ala-Houhala M, Antkainen M, Merenmies J, Rajantie J, et al</AU>
<TI>Early prednisone therapy in Henoch-Schonlein purpura: a randomized double-blind, placebo-controlled trial</TI>
<SO>Journal of Pediatrics</SO>
<YR>2006</YR>
<VL>149</VL>
<NO>2</NO>
<PG>241-7</PG>
<IDENTIFIERS MODIFIED="2009-04-08 13:35:06 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 13:35:06 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16887443"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarshish-2004" MODIFIED="2015-07-13 10:57:14 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Tarshish 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-07-13 10:57:14 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarshish P, Bernstein J, Edelmann C</AU>
<TI>Henoch-Schonlein purpura (HSP) nephritis: efficacy of cytoxan (C) &amp; natural history. Report of the ISKDC [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>4</NO>
<PG>421A</PG>
<IDENTIFIERS MODIFIED="2015-07-13 10:57:14 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 10:57:14 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00486109"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-06 15:47:16 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarshish P, Bernstein J, Edelmann CM Jr</AU>
<TI>Henoch-Schonlein purpura nephritis: course of disease and efficacy of cyclophosphamide</TI>
<SO>Pediatric Nephrology</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>1</NO>
<PG>51-6</PG>
<IDENTIFIERS MODIFIED="2009-04-08 13:50:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 13:50:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="14634864"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2009" MODIFIED="2015-07-09 17:44:24 +1000" MODIFIED_BY="[Empty name]" NAME="Xu 2009" YEAR="2009 Mar">
<REFERENCE MODIFIED="2015-07-09 17:44:24 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu J, Cong H, Sheng Y</AU>
<TI>Efficacy of fosinopril on proteinuria in children with Henoch-Schonlein purpura nephritis</TI>
<SO>Zhongguo Dangdai Erke Zazhi</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>3</NO>
<PG>229-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19292967"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshimoto-1987a" MODIFIED="2015-07-15 19:17:50 +1000" MODIFIED_BY="Narelle S Willis" NAME="Yoshimoto 1987a" YEAR="1987">
<REFERENCE MODIFIED="2015-07-15 19:17:50 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshimoto M, Ito H, Shindo S, Yamashita F</AU>
<TI>Evaluation of the preventive role of dipyridamole and aspirin against renal complication in Schonlein-Henoch purpura [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>C47</PG>
<IDENTIFIERS MODIFIED="2009-04-08 13:53:04 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 13:53:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00445875"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoshimoto-1987b" MODIFIED="2015-07-15 19:17:25 +1000" MODIFIED_BY="Narelle S Willis" NAME="Yoshimoto 1987b" YEAR="1987">
<REFERENCE MODIFIED="2015-07-15 19:17:25 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoshimoto M, Ito H, Shindo S, Yamashita F</AU>
<TI>Evaluation of the preventive role of dipyridamole and aspirin against renal complication in Schonlein-Henoch purpura [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>C47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="CENTRAL" VALUE="CN-00445875"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-07-21 16:08:07 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2010" MODIFIED="2015-07-13 12:27:02 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Chen 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-07-13 12:27:02 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen T, Guo Z-P, Zhang Y-H, Gao Y</AU>
<TI>Effect of MORA bioresonance therapy in the treatment of Henoch-Schonlein purpura and influence on serum antioxidant enzymes</TI>
<SO>Journal of Clinical Dermatology</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>5</NO>
<PG>283-5</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:27:02 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:27:02 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="EMBASE" VALUE="2010397798"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-1995" MODIFIED="2015-07-13 12:28:04 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Ding 1995" YEAR="1995">
<REFERENCE MODIFIED="2015-07-13 12:28:04 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding HL, Cheng JZ</AU>
<TI>Clinical trial of potenlin in allergic purpura of adults</TI>
<SO>Journal of Clinical Dermatology</SO>
<YR>1995</YR>
<VL>24</VL>
<NO>5</NO>
<PG>300-2</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:28:04 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:28:04 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00550728"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erdogan-1999" MODIFIED="2015-07-13 12:28:27 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Erdogan 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-07-13 12:28:27 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="OTHER">
<AU>Erdogan O, Oner A, Aydin A, Isimer A, Demircin G, Bulbul M, et al</AU>
<TI>Lack of efficacy of vitamin e supplementation in decreasing the oxidative damage Henoch-Schonlein Purpura: a randomised controlled trial [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>9</NO>
<PG>A46</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:28:27 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:28:27 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00483878"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fukui-1989" MODIFIED="2015-07-13 12:28:41 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Fukui 1989" YEAR="1989">
<REFERENCE MODIFIED="2015-07-13 12:28:41 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="OTHER">
<AU>Fukui H, Kamitsuji H, Nagao T, Yamada K, Akatsuka J, Inagaki M, et al</AU>
<TI>Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Schönlein purpura. Japanese Pediatric Group</TI>
<SO>Thrombosis Research</SO>
<YR>1989</YR>
<VL>56</VL>
<NO>6</NO>
<PG>667-75</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:28:36 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:28:36 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00067042"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hui_x002d_Lan-2001" MODIFIED="2015-07-13 13:59:42 +1000" MODIFIED_BY="Narelle Willis" NAME="Hui-Lan 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-07-13 13:59:10 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hui-Lan Y</AU>
<TI>Treatment of pediatric purpuric nephritis with Tripterygium wilfordii polyglucoside and radix salviac miltiorrhizae [abstract no: P85]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>8</NO>
<PG>C79</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:29:28 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:29:28 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00445801"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-07-13 13:59:42 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hui-Lan YY</AU>
<TI>Treatment of purpuric nephritis in children with Tripterygium wilfordii polyglucoside and Radix salviae miltiorrhizae [abstract]</TI>
<SO>Pediatric Nephrology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>8</NO>
<PG>C78</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:37:24 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:37:24 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00445799"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jia-2001" MODIFIED="2015-07-13 14:09:35 +1000" MODIFIED_BY="Narelle Willis" NAME="Jia 2001" YEAR="2001 Aug">
<REFERENCE MODIFIED="2015-07-13 14:09:35 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jia WC, Zhang YC, Wei AP</AU>
<TI>Immune functional changes in patients of acute Henoch-Schonlein purpura and regulatory effect of integrated Traditional Chinese and Western medicine on it</TI>
<SO>Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>8</NO>
<PG>585-7</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:29:34 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="12575571"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2003" MODIFIED="2015-07-13 12:30:32 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Jiang 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-07-13 12:30:32 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang Y</AU>
<TI>Therapeutic effect of low-dose hepacarin in the childhood anaphylactoid purpura</TI>
<SO>Journal of Pediatric Pharmacy</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>4</NO>
<PG>58-9</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:30:32 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:30:32 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00583752"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jin-2003" MODIFIED="2015-07-13 14:06:26 +1000" MODIFIED_BY="Narelle Willis" NAME="Jin 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-07-13 14:06:26 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jin ZD, Wang SC, Sun YQ</AU>
<TI>Effect of Danshao granule on serum superoxide dismutase activity and malonyldialdehyde content in children with Henoch-Schonlein purpura nephritis</TI>
<SO>Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>12</NO>
<PG>905-7</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:31:07 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:31:07 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="14714360"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-1987" MODIFIED="2015-07-21 16:08:07 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kim 1987" YEAR="1987">
<REFERENCE MODIFIED="2015-07-21 16:08:07 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kim PK, Jeong HJ, Kim KS, Lee JK, Lee JS, Choi IJ</AU>
<TI>Rifampin therapy in Henoch-Schonlein Purpura nephritis accompanied by the nephrotic syndrome [abstract]</TI>
<SO>10th International Congress of Nephrology; 1987 Jul 26-31; London, UK</SO>
<YR>1987</YR>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2005b" MODIFIED="2015-07-13 14:03:27 +1000" MODIFIED_BY="Narelle Willis" NAME="Lee 2005b" YEAR="2005">
<REFERENCE MODIFIED="2015-07-13 14:03:27 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee JS, Shin J, Park JM, Shin YH, Jeong HJ</AU>
<TI>Can azathioprine and steroids alter the progression of severe Henoch-Schoenlein nephritis in children?</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>Suppl 5</NO>
<PG>v221</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-15 13:08:35 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Jeong HJ</AU>
<TI>Can azathioprine and steroids alter the progression of severe Henoch-Schoenlein nephritis in children? [abstract no: M-PO30047]</TI>
<SO>Nephrology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>Suppl</NO>
<PG>A50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2004a" MODIFIED="2015-07-13 14:05:56 +1000" MODIFIED_BY="Narelle Willis" NAME="Liu 2004a" YEAR="2004 Aug">
<REFERENCE MODIFIED="2015-07-13 14:05:56 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu CS, Gong ZZ, Xiang SH</AU>
<TI>Clinical study on integrative Chinese and Western medicine in treating allergic purpura and preventing renal impairment</TI>
<SO>Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>8</NO>
<PG>701-3</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:32:38 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="15366592"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2008" MODIFIED="2015-07-13 14:04:41 +1000" MODIFIED_BY="Narelle Willis" NAME="Liu 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-07-13 14:04:41 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu QC, Wu WH, Wu DY, Feng XW, Ma YH, Li JY, et al</AU>
<TI>Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue capsule</TI>
<SO>Chinese Journal of Integrative Medicine</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>2</NO>
<PG>132-6</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:33:26 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:33:26 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="18679605"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2011" MODIFIED="2015-07-13 14:05:47 +1000" MODIFIED_BY="Narelle Willis" NAME="Wang 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-07-13 14:05:47 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang ZW, Lu Y, Zhen XF</AU>
<TI>Effect of herbs in early intervention of children with Henoch-Schonlein purpura nephritis</TI>
<SO>Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>4</NO>
<PG>504-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21608223"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xie-2009" MODIFIED="2015-07-13 12:33:57 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Xie 2009" YEAR="2009 Apr">
<REFERENCE MODIFIED="2015-07-13 12:33:57 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xie XL, Kou SR, Xu YH, Li CY</AU>
<TI>Effect of composite salvia injection on platelet parameters in children with anaphylactoid purpura</TI>
<SO>Chinese Journal of Integrative Medicine</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>2</NO>
<PG>149-51</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:33:52 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="19407955"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2010" MODIFIED="2015-07-13 13:51:29 +1000" MODIFIED_BY="Narelle Willis" NAME="Yang 2010" YEAR="2010 Jun">
<REFERENCE MODIFIED="2015-07-13 13:51:29 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang HJ, Zhuang KS, Bu TW, Mu LQ</AU>
<TI>Controlled study on therapeutic effect of vessel pricking therapy and western medication for treatment of Henoch-Schonlein purpura nephritis</TI>
<SO>Zhongguo Zhenjiu</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>6</NO>
<PG>449-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="20578379"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yi-2007" MODIFIED="2015-07-13 13:51:37 +1000" MODIFIED_BY="Narelle Willis" NAME="Yi 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-07-13 13:51:37 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Yi H</AU>
<TI>Effect of Shenyankangfu tablet on urinary IL-6 and its therapeutic effect in children with Henoch-Schonlein purpura nephritis</TI>
<SO>Zhongguo Dangdai Erke Zazhi</SO>
<YR>2007</YR>
<VL>9</VL>
<NO>2</NO>
<PG>153-4</PG>
<IDENTIFIERS MODIFIED="2015-07-13 12:35:32 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:35:32 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="17448314"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1984" MODIFIED="2015-07-13 13:51:48 +1000" MODIFIED_BY="Narelle Willis" NAME="Zhang 1984" YEAR="1984">
<REFERENCE MODIFIED="2015-07-13 13:51:48 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang WZ, Zhou MJ</AU>
<TI>Clinical observation of anisodamine on treatment of anaphylactoid purpura by infused intravenously</TI>
<SO>Chinese Journal of Practical Internal Medicine</SO>
<YR>1984</YR>
<VL>4</VL>
<NO>1</NO>
<PG>26</PG>
<IDENTIFIERS MODIFIED="2015-07-13 13:20:40 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 13:20:40 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00583439"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2009" MODIFIED="2015-07-13 14:08:50 +1000" MODIFIED_BY="Narelle Willis" NAME="Zhao 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-07-13 14:08:50 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao H, Dou ZY, Li YQ</AU>
<TI>Preventive effect of integrative medical therapy on children Henoch-Schonleln purpura with renal impairment</TI>
<SO>Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional &amp; Western Medicine]</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>4</NO>
<PG>351-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19526764"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-07-21 16:08:44 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-2014" MODIFIED="2015-07-13 09:57:29 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Ding 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-07-13 09:57:29 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding D, Yan H, Zhen X</AU>
<TI>Effects of Chinese herbs in children with Henoch-Schonlein purpura nephritis: a randomized controlled trial</TI>
<SO>Journal of Traditional Chinese Medicine</SO>
<YR>2014</YR>
<VL>34</VL>
<NO>1</NO>
<PG>15-22</PG>
<IDENTIFIERS MODIFIED="2015-07-13 09:57:26 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="25102685"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00301613" MODIFIED="2015-07-21 16:08:44 +1000" MODIFIED_BY="Narelle S Willis" NAME="NCT00301613" YEAR="2015">
<REFERENCE MODIFIED="2015-07-21 16:08:44 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Liu ZH</AU>
<TI>To compare the efficacy, safety, tolerability and relapse of MMF vs CTX in the treatment of severe HSPN</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT00301613</SO>
<YR>(accessed 13 July 2015)</YR>
<IDENTIFIERS MODIFIED="2015-07-13 12:24:07 +1000" MODIFIED_BY="Gail Y Higgins"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-07-13 12:23:57 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 12:23:57 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="CTG" VALUE="NCT00301613"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2013b" MODIFIED="2015-07-13 09:58:14 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Wu 2013b" YEAR="2013">
<REFERENCE MODIFIED="2015-07-13 09:58:14 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu L, Mao J, Jin X, Fu H, Shen H, Wang J, et al</AU>
<TI>Efficacy of triptolide for children with moderately severe Henoch-Schonlein purpura nephritis presenting with nephrotic range proteinuria: a prospective and controlled study in China</TI>
<SO>BioMed Research International</SO>
<YR>2013</YR>
<VL>2013</VL>
<PG>292865</PG>
<IDENTIFIERS MODIFIED="2015-07-13 09:58:14 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="24455682"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2014c" MODIFIED="2015-07-13 09:58:37 +1000" MODIFIED_BY="Gail Y Higgins" NAME="Wu 2014c" YEAR="2014 Jun">
<REFERENCE MODIFIED="2015-07-13 09:58:25 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu SH, Liao PY, Chen XQ, Yin PL, Dong L</AU>
<TI>Add-on therapy with montelukast in the treatment of Henoch-Schonlein purpura</TI>
<SO>Pediatrics International</SO>
<YR>2014</YR>
<VL>56</VL>
<NO>3</NO>
<PG>315-22</PG>
<IDENTIFIERS MODIFIED="2015-07-13 09:58:22 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER TYPE="MEDLINE" VALUE="24299021"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-04-20 10:07:27 +1000" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-07-30 11:00:52 +1000" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_REFERENCES MODIFIED="2015-07-30 11:00:52 +1000" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Bergstein-1998" NAME="Bergstein 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bergstein J, Leiser J, Andreoli SP</AU>
<TI>Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy</TI>
<SO>Clinical Nephrology</SO>
<YR>1998</YR>
<VL>49</VL>
<NO>1</NO>
<PG>9-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9491279"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" MODIFIED="2015-07-13 14:12:10 +1000" MODIFIED_BY="Narelle Willis" NAME="Chalmers 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith H Jr</AU>
<TI>Bias in treatment assignment in controlled clinical trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<NO>22</NO>
<PG>1358-61</PG>
<IDENTIFIERS MODIFIED="2009-04-08 14:11:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:11:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="6633598"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Coutinho-2001" MODIFIED="2015-07-13 14:13:10 +1000" MODIFIED_BY="Narelle Willis" NAME="Coutinho 2001" TYPE="JOURNAL_ARTICLE">
<AU>Coutinho HM, Groothoff JW, Offringa M, Gruppen MP, Heymans HS</AU>
<TI>De novo malignancy after paediatric renal replacement therapy</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2001</YR>
<VL>85</VL>
<NO>6</NO>
<PG>478-483</PG>
<IDENTIFIERS MODIFIED="2015-07-13 13:22:51 +1000" MODIFIED_BY="Gail Y Higgins">
<IDENTIFIER MODIFIED="2015-07-13 13:22:51 +1000" MODIFIED_BY="Gail Y Higgins" TYPE="MEDLINE" VALUE="11719332"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davin--2011" MODIFIED="2015-07-13 14:14:42 +1000" MODIFIED_BY="Narelle Willis" NAME="Davin  2011" TYPE="JOURNAL_ARTICLE">
<AU>Davin JC</AU>
<TI>Henoch-Schonlein purpura nephritis: pathophysiology, treatment and future strategy</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>3</NO>
<PG>679-89</PG>
<IDENTIFIERS MODIFIED="2015-07-13 14:14:22 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2015-07-13 14:14:22 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="21393485"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Davin-2013" MODIFIED="2015-07-13 14:16:01 +1000" MODIFIED_BY="Narelle Willis" NAME="Davin 2013" TYPE="JOURNAL_ARTICLE">
<AU>Davin JC, Coppo R</AU>
<TI>Pitfalls in recommending evidence based guidelines for a protean disease like Henoch-Schonlein purpura nephritis</TI>
<SO>Pediatric Nephrology</SO>
<YR>2013</YR>
<VL>28</VL>
<NO>10</NO>
<PG>1897-903</PG>
<IDENTIFIERS MODIFIED="2015-07-13 14:16:01 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2015-07-13 14:16:01 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="23832137"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Du-2012" MODIFIED="2015-07-13 14:17:00 +1000" MODIFIED_BY="Narelle Willis" NAME="Du 2012" TYPE="JOURNAL_ARTICLE">
<AU>Du Y, Zhao C, Han W, Wu Y</AU>
<TI>Treatment of children with Henoch-Schonlein purpura nephritis with mycophenolate mofetil</TI>
<SO>Pediatric Nephrology</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>5</NO>
<PG>765-71</PG>
<IDENTIFIERS MODIFIED="2015-07-13 14:17:00 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2015-07-13 14:17:00 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="22081165"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Flynn-2001" MODIFIED="2015-07-13 14:18:09 +1000" MODIFIED_BY="Narelle Willis" NAME="Flynn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB</AU>
<TI>Treatment of Henoch-Schonlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide</TI>
<SO>American Journal of Nephrology</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>2</NO>
<PG>128-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11359020"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Foster-2000" MODIFIED="2015-07-13 14:18:17 +1000" MODIFIED_BY="Narelle Willis" NAME="Foster 2000" TYPE="JOURNAL_ARTICLE">
<AU>Foster BJ, Bernard C, Drummond KN, Sharma AK</AU>
<TI>Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study</TI>
<SO>Journal of Pediatrics</SO>
<YR>2000</YR>
<VL>136</VL>
<NO>3</NO>
<PG>370-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10700695"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gardner_x002d_Medwin-2002" MODIFIED="2009-04-15 11:20:21 +1000" MODIFIED_BY="[Empty name]" NAME="Gardner-Medwin 2002" TYPE="JOURNAL_ARTICLE">
<AU>Garner-Medwin JM, Dolezalova P, Cummins C, Southwood TR</AU>
<TI>Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<NO>9341</NO>
<PG>1197-202</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12401245"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1992" MODIFIED="2015-07-13 14:19:46 +1000" MODIFIED_BY="Narelle Willis" NAME="Goldstein 1992" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein AR, White RH, Akuse R, Chantler C</AU>
<TI>Long-term follow-up of childhood Henoch Schonlein nephritis</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<NO>8788</NO>
<PG>280-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1346291"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-07-13 14:20:00 +1000" MODIFIED_BY="Narelle Willis" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-07-13 14:22:49 +1000" MODIFIED_BY="Narelle Willis" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated February 2011]. The Cochrane Collaboration. 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iijima-1998" MODIFIED="2009-04-08 14:13:23 +1000" MODIFIED_BY="Narelle S Willis" NAME="Iijima 1998" TYPE="JOURNAL_ARTICLE">
<AU>Iijima R, Ito-Kariya S, Nakamura H, Yoshikowa N</AU>
<TI>Multiple combined therapy for severe Henoch Schonlein nephritis in children</TI>
<SO>Pediatric Nephrology</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>3</NO>
<PG>244-8</PG>
<IDENTIFIERS MODIFIED="2009-04-08 14:13:23 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:13:23 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="9630047"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jennette-2013" MODIFIED="2015-07-13 14:25:50 +1000" MODIFIED_BY="Narelle Willis" NAME="Jennette 2013" TYPE="JOURNAL_ARTICLE">
<AU>Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al</AU>
<TI>2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2013</YR>
<VL>65</VL>
<NO>1</NO>
<PG>1-11</PG>
<IDENTIFIERS MODIFIED="2015-07-13 14:25:32 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2015-07-13 14:25:32 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="23045170"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kawasaki-2004" MODIFIED="2015-07-13 14:27:00 +1000" MODIFIED_BY="Narelle Willis" NAME="Kawasaki 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kawasaki Y, Suzuki J, Suzuki H</AU>
<TI>Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>4</NO>
<PG>858-64</PG>
<IDENTIFIERS MODIFIED="2015-07-13 14:27:00 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2015-07-13 14:27:00 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15031341"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-KDIGO-2012" MODIFIED="2015-07-13 14:28:44 +1000" MODIFIED_BY="Narelle Willis" NAME="KDIGO 2012" TYPE="JOURNAL_ARTICLE">
<TI>KDIGO clinical practice guidelines for glomerulonephritis</TI>
<SO>Kidney International - Supplement</SO>
<YR>2012</YR>
<VL>2</VL>
<PG>139-274</PG>
<IDENTIFIERS MODIFIED="2015-07-13 14:28:44 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2015-07-13 14:28:44 +1000" MODIFIED_BY="Narelle Willis" TYPE="DOI" VALUE="10.1038/kisup.2012.10"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Narchi-2005" MODIFIED="2009-04-08 14:18:36 +1000" MODIFIED_BY="Narelle S Willis" NAME="Narchi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Narchi H</AU>
<TI>Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2005</YR>
<VL>90</VL>
<NO>9</NO>
<PG>916-20</PG>
<IDENTIFIERS MODIFIED="2009-04-08 14:18:20 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:18:20 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="15871983"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Niaudet-1998" NAME="Niaudet 1998" TYPE="JOURNAL_ARTICLE">
<AU>Niaudet P, Habib R</AU>
<TI>Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis</TI>
<SO>Pediatric Nephrology</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>3</NO>
<PG>238-43</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9630046"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ronkainen-2003" MODIFIED="2015-07-13 14:32:33 +1000" MODIFIED_BY="Narelle Willis" NAME="Ronkainen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ronkainen J, Ala-Houhala M, Huttunen NP, Jahnukainen T, Koskimies O, Ormala T, et al</AU>
<TI>Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria</TI>
<SO>Clinical Nephrology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>2</NO>
<PG>80-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12940608"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Saulsbury-1999" NAME="Saulsbury 1999" TYPE="JOURNAL_ARTICLE">
<AU>Saulsbury FT</AU>
<TI>Henoch-Schonlein Purpura in children. Report of 100 patients and review of the literature</TI>
<SO>Medicine</SO>
<YR>1999</YR>
<VL>78</VL>
<NO>6</NO>
<PG>395-409</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10575422"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2015-07-13 14:33:42 +1000" MODIFIED_BY="Narelle Willis" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS MODIFIED="2009-04-08 14:20:54 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:20:54 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="7823387"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shenoy-2007" MODIFIED="2009-04-08 14:22:04 +1000" MODIFIED_BY="Narelle S Willis" NAME="Shenoy 2007" TYPE="JOURNAL_ARTICLE">
<AU>Shenoy M, Ognjanovic MV, Coulthard MG</AU>
<TI>Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone</TI>
<SO>Pediatric Nephrology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>8</NO>
<PG>1167-71</PG>
<IDENTIFIERS MODIFIED="2009-04-08 14:22:04 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:22:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17530298"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shin-2006" MODIFIED="2009-04-08 14:23:04 +1000" MODIFIED_BY="Narelle S Willis" NAME="Shin 2006" TYPE="JOURNAL_ARTICLE">
<AU>Shin JI, Park JM, Shin YH, Hwang DH, Kim JH, Lee JS</AU>
<TI>Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schonlein purpura</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>1</NO>
<PG>56-60</PG>
<IDENTIFIERS MODIFIED="2009-04-08 14:23:04 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:23:04 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16467044"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tanaka-2003" NAME="Tanaka 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tanaka H, Suzuki K, Nakahata T, Ito E, Waga S</AU>
<TI>Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis</TI>
<SO>Pediatric Nephrology</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>4</NO>
<PG>347-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12700960"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weiss-2007" MODIFIED="2009-04-08 14:24:25 +1000" MODIFIED_BY="Narelle S Willis" NAME="Weiss 2007" TYPE="JOURNAL_ARTICLE">
<AU>Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C</AU>
<TI>Effects of corticosteroid on Henoch-Schonlein purpura: a systematic review</TI>
<SO>Pediatrics</SO>
<YR>2007</YR>
<VL>120</VL>
<NO>5</NO>
<PG>1079-87</PG>
<IDENTIFIERS MODIFIED="2009-04-08 14:24:25 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:24:25 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17974746"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2009-04-08 14:27:01 +1000" MODIFIED_BY="Narelle S Willis" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2009-04-08 14:26:59 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:26:59 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18316340"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wyatt-2001" MODIFIED="2015-07-13 14:37:41 +1000" MODIFIED_BY="Narelle Willis" NAME="Wyatt 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wyatt RJ, Hogg RJ</AU>
<TI>Evidence-based assessment of treatment options for children with IgA nephropathies</TI>
<SO>Pediatric Nephrology</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>2</NO>
<PG>156-67</PG>
<IDENTIFIERS MODIFIED="2015-07-13 14:37:41 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2015-07-13 14:37:41 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="11261686"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zaffanello-2007" MODIFIED="2015-07-13 14:38:13 +1000" MODIFIED_BY="Narelle Willis" NAME="Zaffanello 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zaffanello M, Brugnara M, Franchini M</AU>
<TI>Therapy for children with Henoch-Schonlein Purpura nephritis: a systematic review</TI>
<SO>Thescientificworldjournal</SO>
<YR>2007</YR>
<VL>7</VL>
<PG>20-30</PG>
<IDENTIFIERS MODIFIED="2009-04-08 14:30:12 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:30:12 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17221139"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-07-13 14:41:32 +1000" MODIFIED_BY="Narelle Willis">
<REFERENCE ID="REF-Chartapisak-2005" MODIFIED="2009-04-08 14:34:44 +1000" MODIFIED_BY="Narelle S Willis" NAME="Chartapisak 2005" TYPE="COCHRANE_PROTOCOL">
<AU>Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC</AU>
<TI>Interventions for preventing and treating renal disease in Henoch-Schönlein Purpura (HSP)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-04-08 14:34:38 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:34:38 +1000" MODIFIED_BY="Narelle S Willis" TYPE="DOI" VALUE="10.1002/14651858.CD005128"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chartapisak-2008" MODIFIED="2009-04-08 14:32:30 +1000" MODIFIED_BY="Narelle S Willis" NAME="Chartapisak 2008" TYPE="JOURNAL_ARTICLE">
<AU>Chartapisak W, Opastirakul O, Willis NS, Craig JC, Hodson EM</AU>
<TI>Prevention and treatment of renal disease in Henoch-Schönlein Purpura: a systematic review</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>2008</YR>
<VL>94</VL>
<NO>2</NO>
<PG>132-7</PG>
<IDENTIFIERS MODIFIED="2009-04-08 14:32:11 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2009-04-08 14:32:11 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="18701559"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chartapisak-2009" MODIFIED="2015-07-13 14:41:32 +1000" MODIFIED_BY="Narelle Willis" NAME="Chartapisak 2009" TYPE="COCHRANE_REVIEW">
<AU>Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC</AU>
<TI>Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2015-07-13 14:40:35 +1000" MODIFIED_BY="Narelle Willis">
<IDENTIFIER MODIFIED="2015-07-13 14:40:35 +1000" MODIFIED_BY="Narelle Willis" TYPE="DOI" VALUE="10.1002/14651858.CD005128.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-07-09 16:55:43 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Zou-2012" MODIFIED="2013-03-14 14:32:01 +1100" MODIFIED_BY="[Empty name]" NAME="Zou 2012" TYPE="JOURNAL_ARTICLE">
<AU>Zou C, Lu F, Mao W, Liu X</AU>
<TI>Chinese herbal medicine danshen formulations for preventing renal disease in henoch-schonlein purpura: A systematic review and meta-analysis</TI>
<SO>Journal of Alternative and Complementary Medicine</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>4</NO>
<PG>394-401</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-07-21 16:13:11 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-CESAR-Study-2010">
<CHAR_METHODS MODIFIED="2015-07-21 10:17:12 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: open-label, parallel RCT</LI>
<LI>Study time frame: September 2002 to September 2006</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-21 11:29:10 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: France</LI>
<LI>Setting: Multicentre</LI>
<LI>Patients aged 18 to 84 years; biopsy proven diagnosis of HSP-associated with severe involvement of one organ</LI>
<UL>
<LI>HSP diagnosis was based on the Chapel Hill Nomenclature conference criteria</LI>
</UL>
<LI>Number (enrolled/analysed): treatment group (25/17); control group (29/19)</LI>
<LI>Mean age ± SD (years): treatment group (52.8 ± 18.5); control group (60.7 ± 11.0)</LI>
<LI>Sex (M/F): treatment group (17/8); control group (17/12)</LI>
<LI>Exclusion criteria: patients with other causes of purpura (thrombocytopenia, bacterial or other forms of vasculitis); hepatitis B or hepatitis C or HIV infection; receiving immunosuppressants or steroids in the prior two weeks; pregnant or breastfeeding women</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 17:44:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>IV CPA: 0.6 mg/m² on days 1 and 15, and at weeks 4, 8, 12 and 16 (six doses). Maximum dose 1200 mg, and dose reduced according to renal dysfunction</LI>
<LI>IV methylprednisolone: 7.5 mg/kg/d for 3 days</LI>
<LI>Oral prednisone: 1 mg/kg/d from day 4 for 1 week, then tapering to 0.4 mg/kg/d at end of first month; 0.25 mg/kg/d at end of second month, and stopped at end of sixth month</LI>
</UL>
<P>Control group</P>
<UL>
<LI>IV methylprednisolone: 7.5 mg/kg/d for 3 days</LI>
<LI>Oral prednisone: 1 mg/kg/d from day 4 for 1 week, then tapering to 0.4 mg/kg/d at end of first month; 0.25 mg/kg/d at end of second month, and stopped at end of sixth month</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-21 16:13:11 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary outcome</P>
<UL>
<LI>Complete disease remission at month 6 defined as BVAS score of 0, with no persisting or new clinical, biological or both vasculitis activity</LI>
</UL>
<P>Secondary outcomes at 12 months</P>
<UL>
<LI>GFR &lt; 60 mL/min</LI>
<LI>Proteinuria &gt; 1 g/d</LI>
<LI>Blood pressure &gt; 125/75</LI>
<LI>Number with kidney functional improvement &gt; 50%</LI>
<LI>Number with ESKD</LI>
<LI>Adverse events particularly diabetes mellitus and infection</LI>
<LI>Death</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 17:46:50 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding source: Supported by a research grant from the Departement a la Recherche Clinique et au Developpement, Assistance Publique&#8211;Hopitaux de Paris, which also sponsored the study (PHRCAOM01034P011014)</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-21 16:13:20 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Dudley-2013">
<CHAR_METHODS MODIFIED="2015-07-15 17:06:11 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study time frame: January 2001 to January 2005</LI>
<LI>Follow-up period: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-21 16:13:20 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: UK</LI>
<LI>Setting: 24 Paediatric departments in secondary/tertiary hospital</LI>
<LI>Children &lt; 18 years enrolled/randomised within 7 days of onset of HSP rash</LI>
<UL>
<LI>HSP defined as: palpable purpura with arthritis, kidney disease, gut involvement</LI>
<LI>Kidney disease defined as: UPC &gt; 20 mg/mmol; positive dipstick for blood or protein; patients with haematuria, proteinuria or both at study entry were included</LI>
</UL>
<LI>Number</LI>
<UL>
<LI>Treatment group: 181 entered; 180 in study at baseline; 171 in study at 12 months; 150 attended 12 month visit; 123 analysed for primary endpoint (No specimen for UPC at 12 months in 27 of 150)</LI>
<LI>Control group: 171 entered; 170 in study at baseline; 165 in study at 12 months; 146 attended 12 month visit; 124 analysed for primary endpoint (No specimen for UPC at 12 months in 22 of 146)</LI>
</UL>
<LI>Median age, range (years): treatment group (6.34, 1 to 15.7); control group (6.12, 0.5 to 13.9)</LI>
<LI>Sex (M/F): treatment group (93/88); control group (100/72)</LI>
<LI>Exclusion criteria: already on steroids or immunosuppressives; pre-existing kidney disease; hypertension; immunodeficiency; systemic infection; contraindications to steroids; characteristic purpuric rash &gt; 7 days</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 17:14:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Prednisolone: 2 mg/kg/d orally for 7 days (max dose 80 mg); 1 mg/kg/d for 7 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo: given in same regimen</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Additional treatment for gut or kidney disease as steroids (prednisolone (4); placebo (9)); ACEi or ARB (2 prednisolone (2); placebo (3)); other antihypertensives (prednisolone (3); placebo (0))</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-15 17:20:07 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary outcome</P>
<UL>
<LI>Proteinuria at 12 months, defined as UPC &gt; 20 mg/mmol</LI>
</UL>
<P>Secondary outcomes</P>
<UL>
<LI>Possible trial medication induced toxicity defined as reporting of hypertension, abdominal pain, nausea and or vomiting or adverse effects before end of week 4 visit</LI>
<LI>Need for additional therapy</LI>
<LI>Proteinuria or haematuria at 4 weeks, 3 months and 12 months</LI>
<LI>UPC &gt; 200 mg/mmol at 12 months</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 17:19:09 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: 1 in each group</LI>
<LI>Funding source: Wales Office for Research and Development</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Fuentes-2010">
<CHAR_METHODS MODIFIED="2015-07-15 17:22:29 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: not reported</LI>
<LI>Follow-up period: patients followed up for one year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-15 17:27:14 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Mexico</LI>
<LI>Setting: tertiary Children's Hospital</LI>
<LI>Children with biopsy proven HSP (ISKDC histology class 1 (1); class 2 (6); class 3 (10))</LI>
<LI>Number: treatment group 1 (8); treatment group 2 (9)</LI>
<LI>Mean age ± SD (years): treatment group 1 (6.4 ± 1.5); treatment group 2 (7.4 ± 2)</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 17:27:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group 1</P>
<UL>
<LI>AZA: dosage not reported</LI>
<LI>Prednisone: dosage not reported</LI>
</UL>
<P>Treatment group 2</P>
<UL>
<LI>MMF: dosage not reported</LI>
<LI>Prednisone: dosage not reported</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-15 17:28:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>Primary outcomes</P>
<UL>
<LI>Regression of histological lesion</LI>
<LI>Improvement in proteinuria</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 17:30:05 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only available</LI>
<LI>Further information received from authors: anaemia in one patient in the MMF arm</LI>
<LI>One author consultant for Novartis, Mexico</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-15 17:38:14 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-He-2002">
<CHAR_METHODS MODIFIED="2015-07-15 17:33:46 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Duration of study: not reported</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-15 17:36:24 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: China</LI>
<LI>Setting: university hospital</LI>
<LI>Children at onset or relapse of HSP but presumed to be without kidney disease</LI>
<LI>Number: treatment group (119); control group (109)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 17:37:29 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Heparin: sodium heparin 120 to 150 IU/kg/d IV for 5 days or calcium heparin 10 IU/kg/ subcutaneously twice daily for 7 days given at onset or relapse of HSP</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo injection only</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Vitamin C, vitamin P</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 10:52:25 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Total number of children with kidney disease after 3 months or more (not defined)</LI>
<LI>Number with haematuria and proteinuria after 3 months or more</LI>
<LI>Number with nephrotic syndrome after 3 months or more</LI>
<LI>Time to development of kidney disease</LI>
<LI>Bleeding</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 17:38:14 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only available</LI>
<LI>Funding source: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-15 17:51:36 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Huber-2004">
<CHAR_METHODS MODIFIED="2015-07-15 17:41:14 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: September 1996 to January 2000</LI>
<LI>Follow-up period: One year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-15 17:51:06 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Canada</LI>
<LI>Setting: emergency department in tertiary hospital</LI>
<LI>Children 2 to 15 years within 7 days of onset of HSP</LI>
<UL>
<LI>HSP defined as: palpable purpura and 1 or more of arthritis, kidney disease or gut involvement</LI>
<LI>Kidney disease defined as: haematuria 5 or more RBC/HPF or RBC casts, proteinuria 0.3g/L or more, hypertension 90th percentile for age/sex or above.</LI>
<LI>Study included 4 children in prednisone group and 2 in placebo group with kidney disease at study entry</LI>
</UL>
<LI>Number: treatment group (21); control group (19)</LI>
<LI>Median age, range (years): treatment group (5, 2 to 11): control group (6.1, 3 to 15)</LI>
<LI>Sex (M/F): treatment group (13/8); control group (7/12)</LI>
<LI>Exclusion criteria: known underlying systemic vasculitis; steroids in previous month; underlying kidney, gastrointestinal or immunodeficiency illness; active infection; a life threatening complication of HSP</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 17:50:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Prednisone: 2 mg/kg orally daily for 7 days; reducing dose over 7 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo: given in same regimen</LI>
</UL>
<P>Co-interventions: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-15 17:50:08 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>New or persistent kidney disease at 1 year</LI>
<LI>Gastrointestinal involvement</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 17:51:36 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding source: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Islek-1999">
<CHAR_METHODS MODIFIED="2015-07-15 17:57:09 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: September 1996 to January 2000</LI>
<LI>Duration of follow-up: unclear</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-15 18:01:12 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Turkey</LI>
<LI>Setting: university paediatric clinic</LI>
<LI>Children aged 9.2 ± 2.7 years with HSP without haematuria/proteinuria on admission</LI>
<LI>Defined as non-thrombocytopenic purpura, arthritis and arthralgia, abdominal pain, gastrointestinal haemorrhage</LI>
<LI>Number: treatment group (70); control group (50)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): 69/48</LI>
<LI>Exclusion criteria: kidney disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 17:59:21 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Prednisolone: 1 mg/kg/d for 10 days; tapered over 1 week and withdrawn</LI>
</UL>
<P>Control group </P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-21 16:13:37 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Haematuria, proteinuria or both: no definitions provided</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 17:59:42 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only available</LI>
<LI>Funding source: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-21 15:49:01 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Jauhola-2010">
<CHAR_METHODS MODIFIED="2015-07-15 18:03:14 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Study time frame: December 1999 to April 2006</LI>
<LI>Follow-up period: 2.9 years (1.1 to 5.6)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-21 11:29:16 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Finland</LI>
<LI>Setting: University hospitals</LI>
<LI>Inclusion criteria</LI>
<LI>Kidney biopsy diagnosis of crescentic HSP-associated kidney disease of ISKDC grade III or IV or grade II with nephrotic syndrome</LI>
<LI>Number: treatment group (7); control group (8); 9 patients non-randomised</LI>
<LI>Mean age, range (years): treatment group (9.2, 2 to 18); control group (7.9, 4.0 to 14.8)</LI>
<LI>Sex (M/F): treatment group (5/2); control group (6.2)</LI>
<LI>Exclusion criteria: medication known to interact with CSA</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-21 15:49:01 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>CSA: 5 mg/kg/d for 12 months, titrated according to CSA level</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Methylprednisolone: 30 mg/kg IV x 3 in 1 week</LI>
<LI>Prednisone 30 mg/m²/d for 1 month and tapered over 3 months</LI>
<UL>
<LI>Intermediate days and one month after methylprednisolone patients received oral prednisone 30mg/m<SUP>2</SUP> in 2 daily doses, medication</LI>
</UL>
</UL>
<P>Co-interventions</P>
<UL>
<LI>ACEi</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-15 18:30:34 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Remission (UPC &lt; 200 or urine protein &lt; 40 mg/m²/h) at 3 months</LI>
<LI>Remission at last follow-up</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 18:31:17 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding source: OJ and JR received a grant from the Alma and K A Snellman Foundation, Oulu, Finland and from the Foundation for Paediatric Research for writing this report</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-21 16:13:48 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mollica-1992">
<CHAR_METHODS MODIFIED="2015-07-15 18:34:51 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: October 1978 to September 1987</LI>
<LI>Follow-up period: 24 to 36 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-21 16:13:48 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: university hospital</LI>
<LI>Unselected children with HSP without kidney disease at study entry</LI>
<LI>Treatment group - prednisone</LI>
<LI>Number: treatment group (84); control group (84)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Exclusion criteria: 34 children with haematuria, proteinuria or both on initial presentation</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 18:36:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Prednisolone: 1 mg/ kg orally for 2 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 10:51:33 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Number of patients who develop HSP kidney disease with 2 or more of:</LI>
<UL>
<LI>proteinuria &#8805; 4 mg/m²/h</LI>
<LI>haematuria &#8805;&gt; 10 RBC/HPF</LI>
<LI>BP &#8805; 2 SD above normal for age</LI>
<LI>BUN &#8805; 54 mg/dL</LI>
<LI>Cr &#8805; 0.8 mg/dL/m²</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 18:37:43 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding source: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-21 16:05:54 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Peratoner-1990">
<CHAR_METHODS MODIFIED="2015-07-15 18:38:44 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: not reported</LI>
<LI>Follow-up period: 1 year</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-21 16:05:54 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: multicentre paediatric centres (12)</LI>
<LI>Inclusion criteria</LI>
<LI>Children aged 2 to 14 year old with HSP</LI>
<LI>Treatment group</LI>
<LI>- dipyridamole, salicylates, cyproheptadine</LI>
<LI>Number/kidney disease at entry: treatment group (60/13); control group (41/6)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 18:51:15 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Dipyridamole: 4 mg/kg/d orally in 3 doses</LI>
<LI>Cyproheptadine: 0.5 mg/kg/d orally in 3 doses</LI>
<LI>Salicylates: 10 mg/kg/d orally in one dose for 8 weeks.</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No treatment</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Antipyretics, antibiotics</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-15 18:50:22 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Kidney disease during 1 year of follow-up, assessed using the following scoring system:</LI>
<UL>
<LI>haematuria &gt; 5 RBC/mm³ (score 0 to 2)</LI>
<LI>cylindruria (0-1)</LI>
<LI>hypertension (0-1)</LI>
<LI>reduced CrCl (0-2)</LI>
</UL>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 18:51:30 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding source: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-15 19:02:39 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ronkainen-2006a">
<CHAR_METHODS MODIFIED="2015-07-15 18:53:11 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 1999 to 2005</LI>
<LI>Follow-up period: mean 7.7 years 9 range 4.6 to 11.4 years)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-15 19:00:23 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Finland</LI>
<LI>Setting: university and district hospitals (14)</LI>
<LI>Children &#8804; 16 years; clinical diagnosis of newly diagnosed HSP (purpura, petechiae ± gut/joint pain)</LI>
<LI>Treatment group - prednisone</LI>
<LI>Number (analysed/randomised): treatment group (84/87); control group (87/89)</LI>
<LI>Mean age, range (years): treatment group (6.8, 2.0 to 15.2); control group (7.3, 1.7 to 15.6)</LI>
<LI>Sex (M/F): treatment group (49/35); control group (44/43)</LI>
<LI>Duration of disease at entry (mean days, range): treatment group (4.7, 0 to 28); control group (6.4, 0 to 63)</LI>
<LI>Exclusion criteria: established kidney disease (haematuria &gt; 10 RBC/HPF or proteinuria &gt; 300 mg/L on initial presentation); thrombocytopenia; systemic vasculitis; prednisone contraindicated</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 19:00:46 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Prednisone: 1 mg/kg/d orally for 14 days; 0.5 mg/kg/d for 7 days; 0.5 mg/kg on alternate days for 7 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo tablets</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Paracetamol for pain</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-15 19:02:39 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Long-term outcome patients in a placebo-controlled prednisone study</LI>
<LI>Haematuria: urinary &gt; 5 RBC/HPF at 1, 3, 6 months</LI>
<LI>Proteinuria: urinary protein &gt; 200 mg/L or albumin &gt; 30 mg/L at 1, 3, 6 months</LI>
<LI>Severity and duration of abdominal pain during first month</LI>
<LI>Severity and duration of joint pain during first month</LI>
<LI>Adverse effects: weight; BP</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 19:02:22 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre-intervention: 3 excluded from prednisone group and 2 from placebo group after randomisation</LI>
<LI>Funding source: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-15 19:09:30 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Tarshish-2004">
<CHAR_METHODS MODIFIED="2015-07-15 19:04:59 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 1973 to 1980</LI>
<LI>Follow-up period: 6.93 ± 3.32 years in patients who recovered; 6.57 ± 4.1 years in group with persistent abnormalities; 3.71 ± 2.14 years in patients progressing to ESKD</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-15 19:08:25 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Countries: Europe, USA, Canada</LI>
<LI>Setting: multicentre tertiary</LI>
<LI>Age &gt; 12 weeks to 16 years; HSP: purpura plus urticaria with one or more of the following: joint pain and swelling, kidney disease, abdominal pain and intestinal bleeding; eGFR &gt; 35 mL/min/1.73 m²; proteinuria &gt; 40 mg/m²/h for &gt; 1 month; histopathology: Crescents/segmental lesions (ISKDC classification)</LI>
<LI>Number: treatment group (28); control group (28)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Exclusion criteria: HSP present &gt; 3 months; prior use of immunosuppressive or cytotoxic therapy other than steroids; concurrent or pre-existing kidney disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 19:08:04 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>CPA: 90 mg/m²/d orally for 42 days</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No therapy</LI>
</UL>
<P>Co-interventions</P>
<UL>
<LI>Diet modification, ion exchange resins, vitamins, diuretics</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 10:52:19 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Total number of patients with any persistent kidney disease</LI>
<LI>Number with severe kidney disease (decreased GFR, severe proteinuria, ESKD)</LI>
<LI>Number of patients with ESKD</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 19:09:30 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding source: "Financial support by National Institutes of Health Research Grant 1-RO1-AM18234, the National Kidney Foundation of New York, the Kidney Disease Institute of the State of New York, the William Beaumont Hospital Pathology Projects Fund, the John Rath Foundation, the National Kidney Research Foundation (United Kingdom), and the Kidney Foundation of the Netherlands."</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-15 19:14:09 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Xu-2009">
<CHAR_METHODS MODIFIED="2015-07-15 19:11:04 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: January 2007 to March 2008</LI>
<LI>Duration of follow-up: 2 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-15 19:12:58 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: China</LI>
<LI>Setting: tertiary hospital</LI>
<LI>Children with HSP aged 4 to 14 years; proteinuria &#8805; 150 mg/d; medications ceased 2 weeks prior to study</LI>
<LI>Number: treatment group (27); control group (21)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): 28/20</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 19:13:56 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fosinopril : &lt; 5 years 5 mg daily 8 weeks, 5 to 12 years 10 mg daily 8 weeks</LI>
<LI>Standard therapy: penicillin, clarityne, fraxiparine, dipyridamole, nifedipine and low salt diet</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Standard therapy: penicillin, clarityne, fraxiparine, dipyridamole, nifedipine and low salt diet</LI>
</UL>
<P>Co-interventions: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-06 15:41:23 +1100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Proteinuria &lt; 150 mg</LI>
<LI>Adverse effects</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 19:14:09 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Funding source: not reported</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-15 19:24:41 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Yoshimoto-1987a">
<CHAR_METHODS MODIFIED="2015-07-15 19:15:32 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: October 1984 to September 1985</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-15 19:21:56 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Japan</LI>
<LI>Setting: emergency department in tertiary hospital</LI>
<LI>Children admitted with HSP without kidney disease aged 3 to 10 years</LI>
<LI>Number: treatment group (9); control group (9)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): 13/15</LI>
<LI>Exclusion criteria: known underlying systemic vasculitis; steroids in previous month; underlying kidney, gastrointestinal or immunodeficiency illness; active infection; a life threatening complication of HSP</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 19:22:18 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Aspirin: 5 mg/kg/d for 5 weeks</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Vitamin pills for 5 weeks</LI>
</UL>
<P>Co-interventions: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-05-14 10:51:07 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Number of patient who has kidney disease (not defined); time of involvement not specified</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 19:24:41 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only available</LI>
<LI>Same study as <LINK REF="STD-Yoshimoto-1987b" TYPE="STUDY">Yoshimoto 1987b</LINK>; 2 treatment arms, 1 control</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-07-15 19:24:36 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Yoshimoto-1987b">
<CHAR_METHODS MODIFIED="2015-07-15 19:24:04 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: October 1984 to September 1985</LI>
<LI>Duration of follow-up: not reported</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-07-15 19:24:07 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Japan</LI>
<LI>Setting: emergency department in tertiary hospital</LI>
<LI>Children admitted with HSP without kidney disease aged 3 to 10 years</LI>
<LI>Number: treatment group (10); control group (9)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): 13/15</LI>
<LI>Exclusion criteria: known underlying systemic vasculitis; steroids in previous month; underlying kidney, gastrointestinal or immunodeficiency illness; active infection; a life threatening complication of HSP</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-07-15 19:23:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Dipyridamole: mg/kg/d for 5 weeks</LI>
</UL>
<P>Control group:</P>
<UL>
<LI>Vitamin pills for 5 weeks</LI>
</UL>
<P>Co-interventions: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-07-15 19:23:45 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Number of patients with kidney disease not defined and time of involvement not specified</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-07-15 19:24:36 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Abstract only available</LI>
<LI>Same study as <LINK REF="STD-Yoshimoto-1987a" TYPE="STUDY">Yoshimoto 1987a</LINK>; 2 treatment arms, 1 control</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACEi - angiotensin converting enzyme inhibitor; ARB - angiotensin receptor blocker; AZA - azathioprine; BP - blood pressure; BUN - blood urea nitrogen; BVAS - Birmingham Vascular Activity Score; CPA - cyclophosphamide; Cr - creatinine; CrCl - creatinine clearance; CSA - cyclosporin; eGFR - estimated glomerular filtration rate; ESKD - end-stage kidney disease; GFR - glomerular filtration rate; HIV - human immunodeficiency virus; HPF - high power field; HSP - Henoch-Schönlein Purpura; ISKDC - International Study of Kidney Disease in Children; IV - intravenous; M/F - male/female; MMF - mycophenolate mofetil; RBC - red blood cells; RCT - randomised controlled trial; SCr - serum creatinine; SD - standard deviation; UPC - urinary protein:creatinine ratio<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-08-15 13:13:48 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-15 13:13:48 +1000" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-31 14:28:17 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ding-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-31 14:28:17 +1100" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-18 17:56:30 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Erdogan-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-18 17:56:30 +1100" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-18 17:52:46 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fukui-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-18 17:52:46 +1100" MODIFIED_BY="[Empty name]">
<P>Unclear whether study is RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-18 18:19:33 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hui_x002d_Lan-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-18 18:19:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-18 18:19:38 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Jia-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-18 18:19:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-18 17:54:07 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-18 17:54:07 +1100" MODIFIED_BY="[Empty name]">
<P>Unclear whether study is RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-18 18:19:43 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Jin-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-18 18:19:43 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-15 13:14:08 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-15 13:14:08 +1000" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-15 13:14:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2005b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-15 13:14:19 +1000" MODIFIED_BY="[Empty name]">
<P>Retrospective study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-15 13:13:02 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-15 13:13:02 +1000" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-07-18 18:19:52 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Liu-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-07-18 18:19:52 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ineligible population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-15 13:15:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-15 13:15:21 +1000" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-15 13:13:13 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xie-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-15 13:13:13 +1000" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-15 13:13:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-15 13:13:23 +1000" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-18 18:00:25 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-18 18:00:25 +1100" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-18 18:00:32 +1100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-18 18:00:32 +1100" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-15 13:13:37 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-15 13:13:37 +1000" MODIFIED_BY="[Empty name]">
<P>Ineligible intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-07-13 12:23:42 +1000" MODIFIED_BY="Gail Y Higgins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Ding-2014">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-NCT00301613">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Wu-2013b">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Wu-2014c">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-05-14 10:50:47 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-07-15 17:40:18 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 10:00:55 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CESAR-Study-2010">
<DESCRIPTION>
<P>Central randomisation with computer generated random allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:01:12 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="YES" STUDY_ID="STD-Dudley-2013">
<DESCRIPTION>
<P>Computer generated random number sequence using random number generator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-08 17:02:15 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuentes-2010">
<DESCRIPTION>
<P>Computer generated random numbers. Information provided by authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 13:33:10 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-He-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-15 17:40:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Huber-2004">
<DESCRIPTION>
<P>Computer generated sequence of random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 10:38:57 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Islek-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-08 17:06:54 +1100" MODIFIED_BY="Elisabeth M Hodson" RESULT="YES" STUDY_ID="STD-Jauhola-2010">
<DESCRIPTION>
<P>Randomised by a central office</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 11:41:16 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Mollica-1992">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 12:14:30 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Peratoner-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-06 15:39:17 +1100" MODIFIED_BY="Elisabeth M Hodson" RESULT="YES" STUDY_ID="STD-Ronkainen-2006a">
<DESCRIPTION>
<P>Block randomisation scheme with block size of 6</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 13:10:33 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Tarshish-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-22 14:36:18 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2009">
<DESCRIPTION>
<P>Randomised but no method mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 13:42:50 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 21:26:42 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987b">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-07-15 17:51:45 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 10:01:04 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CESAR-Study-2010">
<DESCRIPTION>
<P>Central randomisation with computer generated random allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:01:35 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="YES" STUDY_ID="STD-Dudley-2013">
<DESCRIPTION>
<P>Identical bottles for active and placebo medications coded centrally with trial numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-08 17:02:24 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuentes-2010">
<DESCRIPTION>
<P>Computer generated. Information provided by authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 13:33:19 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-He-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-15 17:51:45 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Huber-2004">
<DESCRIPTION>
<P>Plain sealed numbered envelopes opened at subject randomisation by research pharmacist. Individuals directly involved in the study had no access to these envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 10:39:07 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Islek-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-16 14:12:05 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="YES" STUDY_ID="STD-Jauhola-2010">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 11:42:08 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="NO" STUDY_ID="STD-Mollica-1992">
<DESCRIPTION>
<P>Each patient on entry to the trial was alternatively assigned to one of the two treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 12:14:54 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Peratoner-1990">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-06 15:39:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ronkainen-2006a">
<DESCRIPTION>
<P>Observers and subjects were unaware of randomisation scheme. Pharmia Ltd packed drugs, labelled containers, performed randomisation and retained key to randomisation till end of study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 13:13:17 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="YES" STUDY_ID="STD-Tarshish-2004">
<DESCRIPTION>
<P>Random allocation at central office</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-22 14:33:21 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2009">
<DESCRIPTION>
<P>Said to be randomised but no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 13:42:57 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987a">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 21:26:50 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987b">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-10-01 15:27:22 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-07-21 16:06:28 +1000" MODIFIED_BY="Narelle S Willis" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-09-16 12:06:36 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-CESAR-Study-2010">
<DESCRIPTION>
<P>No blinding and outcome is likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-08 17:00:47 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dudley-2013">
<DESCRIPTION>
<P>Trial medications (active and placebo) supplied by same company in identical bottles. Patients, parents, paediatricians and all investigators were blind to treatment management</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-11-21 09:48:45 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fuentes-2010">
<DESCRIPTION>
<P>No blinding and outcome is likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-15 17:38:32 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-He-2002">
<DESCRIPTION>
<P>Control group given IV vehicle but unclear whether investigators aware of which patients received heparin or vehicle</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-21 15:48:44 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Huber-2004">
<DESCRIPTION>
<P>Prednisone and placebo groups received identical number of pills and followed the same schedule.</P>
<P>Prednisone and placebo tablets placed in opaque tasteless gelatin capsules</P>
<P>The subjects and all individuals involved in the enrolment and assessment of study participants were blinded to the study group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-01 15:32:52 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Islek-1999">
<DESCRIPTION>
<P>No placebo tablets administered in the control group. No information provided on whether outcome assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-15 18:31:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jauhola-2010">
<DESCRIPTION>
<P>Open-label study comparing an orally administered agent with an intravenously administered agent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-01 15:33:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mollica-1992">
<DESCRIPTION>
<P>Control group did not receive placebo medications.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-15 18:51:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Peratoner-1990">
<DESCRIPTION>
<P>No placebo given to control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-02-06 15:39:18 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ronkainen-2006a">
<DESCRIPTION>
<P>Prednisone (5 mg tablets) and placebo were similar in size and supplied in lots of 200 tablets in similar containers marked with sequential numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-07-21 16:06:28 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Tarshish-2004">
<DESCRIPTION>
<P>No placebo therapy used. While most outcome measures were laboratory measurements and unlikely to be influenced by lack of blinding, end points in some children were judged on dipstick protein urinalyses, which could have be either doctor or patient reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-17 14:50:24 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xu-2009">
<DESCRIPTION>
<P>No blinding and outcome is likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-10-01 16:00:35 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yoshimoto-1987a">
<DESCRIPTION>
<P>Control group received vitamin pills. Outcome measures not defined.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-01-06 09:59:12 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yoshimoto-1987b">
<DESCRIPTION>
<P>Control group received vitamin pills. Outcome measures not defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-07-21 16:06:09 +1000" MODIFIED_BY="Narelle S Willis" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-09-16 12:06:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-CESAR-Study-2010">
<DESCRIPTION>
<P>No blinding and outcome is likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-02 17:02:01 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dudley-2013">
<DESCRIPTION>
<P>Patients, parents, paediatricians and all investigators were blind to outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-11-21 09:48:45 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fuentes-2010">
<DESCRIPTION>
<P>No blinding and outcome is likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-15 17:38:31 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-He-2002">
<DESCRIPTION>
<P>Control group given IV vehicle but unclear whether investigators aware of which patients received heparin or vehicle</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-21 15:48:48 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Huber-2004">
<DESCRIPTION>
<P>The subjects and all individuals involved in the enrolment and assessment of study participants were blinded to the study group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-01 15:33:00 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Islek-1999">
<DESCRIPTION>
<P>No information provided on whether outcome assessors were blinded. Abstract only</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-15 18:31:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jauhola-2010">
<DESCRIPTION>
<P>Open-label study comparing an orally administered agent with an intravenously administered agent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-21 16:05:37 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Mollica-1992">
<DESCRIPTION>
<P>No information provided on whether outcome assessors were blinded. Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-07-21 16:06:09 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Peratoner-1990">
<DESCRIPTION>
<P>No information provided about outcome assessors. Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-01 15:40:03 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ronkainen-2006a">
<DESCRIPTION>
<P>Assessors blinded until end of trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-01 15:54:24 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tarshish-2004">
<DESCRIPTION>
<P>No information provided on outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-01-17 14:50:26 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xu-2009">
<DESCRIPTION>
<P>No blinding and outcome is likely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-01 16:01:05 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987a">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-10-23 21:28:51 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987b">
<DESCRIPTION>
<P>Insufficient data to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-07-21 10:07:04 +1000" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-13 15:03:45 +1000" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-CESAR-Study-2010">
<DESCRIPTION>
<P>All patients accounted for</P>
<P>Loss to follow-up: treatment group (8: death (1), lack of efficacy (1); patient choice (3); adverse event (1); not evaluated (2)); control group (10: deaths (6); lack of efficacy (2); patient choice (1); not evaluated (1))</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-02 17:04:22 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dudley-2013">
<DESCRIPTION>
<P>Lost to follow-up: 10 in prednisone group and 6 in placebo group</P>
<P>Primary outcome analysed in 71% (123/171) in prednisone group and 75% (124/165) in placebo group </P>
<P>Secondary outcome of haematuria or proteinuria analysed in 82% (141/171) in prednisone group and 83% (137/165) in placebo group </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-19 08:29:11 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuentes-2010">
<DESCRIPTION>
<P>All patients accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-21 10:07:04 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-He-2002">
<DESCRIPTION>
<P>No information provided although all patients appeared to have been followed. Minimum follow-up 6 months. Limited information on adverse effects provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-15 17:40:13 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Huber-2004">
<DESCRIPTION>
<P>One subject enrolled declined randomisation</P>
<P>Three children withdrawn from the placebo group due to complications but included in the analysis (intussusception (2); severe rash (1))</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-04-08 15:40:30 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Islek-1999">
<DESCRIPTION>
<P>Unclear whether all eligible patients entered and completed the trial and whether there was any missing data. All reported patients appeared to have completed study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-15 18:32:57 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Jauhola-2010">
<DESCRIPTION>
<P>No SD provided with means of urinary protein and SCr at last follow-up. Duration of study not defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-15 18:34:34 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Mollica-1992">
<DESCRIPTION>
<P>19 patients excluded because of insufficient or inadequate follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-25 15:44:27 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Peratoner-1990">
<DESCRIPTION>
<P>Unclear whether all entered patients completed trial and were included in the results</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-07-15 18:52:16 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Ronkainen-2006a">
<DESCRIPTION>
<P>Three (2 dropped out; 1 protocol violation) excluded from prednisone group. Two (both dropped out) excluded from placebo group. These unlikely to influence final results</P>
<P>138/176 (21%) screened on long-term follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-04-08 18:12:36 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Tarshish-2004">
<DESCRIPTION>
<P>Duration of follow-up variable and unclear whether all patients completed follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-22 16:15:15 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2009">
<DESCRIPTION>
<P>All enrolled patients accounted for </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-04-20 10:05:14 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987a">
<DESCRIPTION>
<P>Criteria for kidney disease not defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-10-23 21:29:24 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987b">
<DESCRIPTION>
<P>Criteria for kidney disease not defined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-07-21 16:13:29 +1000" MODIFIED_BY="Narelle S Willis" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 10:02:37 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CESAR-Study-2010">
<DESCRIPTION>
<P>Reported all outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:05:54 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dudley-2013">
<DESCRIPTION>
<P>Primary outcome pre-specified as UPC in National Research Register of NHS in UK. Information also provided on dipstick analysis of haematuria and proteinuria. Adverse events reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-19 08:11:13 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fuentes-2010">
<DESCRIPTION>
<P>Data on kidney outcomes and adverse effects provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-15 17:38:30 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-He-2002">
<DESCRIPTION>
<P>Information provided on numbers with haematuria alone, haematuria and proteinuria, haematuria with nephrotic syndrome and adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-21 16:13:29 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Huber-2004">
<DESCRIPTION>
<P>Reported that children with persistent kidney disease had haematuria, proteinuria or both and did not have hypertension or kidney insufficiency</P>
<P>Reported adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-15 14:52:18 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Islek-1999">
<DESCRIPTION>
<P>Only outcomes reported were haematuria and proteinuria. No reports separately of more severe kidney disease (acute nephritic syndrome, nephrotic syndrome, hypertension).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-12 13:59:51 +1100" MODIFIED_BY="Elisabeth M Hodson" RESULT="YES" STUDY_ID="STD-Jauhola-2010">
<DESCRIPTION>
<P>Data on kidney outcomes and adverse effects provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-12 13:53:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Mollica-1992">
<DESCRIPTION>
<P>Information on the numbers with proteinuria, haematuria, hypertension and reduced kidney function provided; no report on adverse effects.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-15 18:51:38 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Peratoner-1990">
<DESCRIPTION>
<P>Information on type of residual kidney disease provided in text. No report of adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-06 15:39:25 +1100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ronkainen-2006a">
<DESCRIPTION>
<P>Data on kidney outcomes extrapolated from graphs. Data on adverse effects included</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-08 16:51:11 +1000" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Tarshish-2004">
<DESCRIPTION>
<P>Data on persistent abnormalities, severe abnormalities and ESKD provided though detailed information on GFR and urinary protein excretion at follow-up not provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-22 14:33:34 +1100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2009">
<DESCRIPTION>
<P>Reported all expected outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-12 14:00:49 +1100" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987a">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-12 14:00:28 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987b">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 16:29:15 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-CESAR-Study-2010">
<DESCRIPTION>
<P>Funded by Département a la Recherche Clinique et au Dévelopment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-02 17:08:48 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="YES" STUDY_ID="STD-Dudley-2013">
<DESCRIPTION>
<P>Appears to be free of other biases. Funded by Wales Office for Research and Development</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Fuentes-2010">
<DESCRIPTION>
<P>One author a consultant for Novartis; no full-text publication after 5 years</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-15 17:38:24 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-He-2002">
<DESCRIPTION>
<P>Insufficient information provided.</P>
<P>Unclear as to whether same patient could enter the trial twice (at onset or at recurrence)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 10:31:03 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="YES" STUDY_ID="STD-Huber-2004">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Islek-1999">
<DESCRIPTION>
<P>Insufficient information available to determine however study not published 16 years after abstract first presented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 13:09:13 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Jauhola-2010">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 11:44:49 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Mollica-1992">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 12:21:51 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Peratoner-1990">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 12:47:03 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="YES" STUDY_ID="STD-Ronkainen-2006a">
<DESCRIPTION>
<P>Appears to be free of other biases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 16:05:34 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Tarshish-2004">
<DESCRIPTION>
<P>Insufficient information provided on study design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-07-15 19:14:35 +1000" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2009">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 13:48:25 +1000" MODIFIED_BY="Elisabeth M Hodson" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987a">
<DESCRIPTION>
<P>Insufficient information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-23 21:30:13 +1100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yoshimoto-1987b">
<DESCRIPTION>
<P>Insufficient information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-07-21 16:47:23 +1000" MODIFIED_BY="Narelle S Willis">Prednisone versus placebo or supportive treatment for preventing persistent kidney disease in patients with Henoch-Schönlein Purpura (HSP)</TITLE>
<TABLE COLS="7" ROWS="35">
<TR>
<TD COLSPAN="7">
<P>
<B>Prednisone versus placebo or supportive treatment for preventing persistent kidney disease in patients with Henoch-Schönlein Purpura (HSP)</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with HSP<BR/>
<B>Settings: </B>all settings<BR/>
<B>Intervention:</B> prednisone<BR/>
<B>Comparison: </B>placebo or supportive treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo or supportive treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Prednisone</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Persistent kidney disease at any time after treatment</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.74 </B>
<BR/>(0.42 to 1.32)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>746 (5)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>143 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>106 per 1000</B>
<BR/>(60 to 189)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>105 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>78 per 1000</B>
<BR/>(44 to 139)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Number of children with any continuing kidney disease at 3 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.83 </B>
<BR/>(0.46 to 1.52)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>655 (4)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>199 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>165 per 1000</B>
<BR/>(92 to 303)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>156 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>129 per 1000</B>
<BR/>(72 to 237)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Number of children with any continuing kidney disease at 6 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.51 </B>
<BR/>(0.24 to 1.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>379 (3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>51 per 1000</B>
<BR/>(24 to 111)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>27 per 1000</B>
<BR/>(13 to 59)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Number of children with any continuing kidney disease at 12 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.06 </B>
<BR/>(0.38 to 2.91)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>455 (3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>84 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>89 per 1000</B>
<BR/>(32 to 244)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>105 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>111 per 1000</B>
<BR/>(40 to 306)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Any continuing kidney disease at 3 months (study with high risk of bias excluded)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.98 </B>
<BR/>(0.7 to 1.36)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>487 (3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>243 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>238 per 1000</B>
<BR/>(170 to 330)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>207 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>203 per 1000</B>
<BR/>(145 to 282)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Any continuing kidney disease at 12 months (study with high risk of bias excluded)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.39 </B>
<BR/>(0.75 to 2.59)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>287 (2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>105 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>146 per 1000</B>
<BR/>(79 to 272)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>105 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>146 per 1000</B>
<BR/>(79 to 272)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Number developing severe kidney disease</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.58 </B>
<BR/>(0.42 to 6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>418 (2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>3,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>14 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
<BR/>(6 to 85)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>27 per 1000</B>
<BR/>(7 to 102)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Two studies had unclear or biased allocation concealment &amp; were not blinded<BR/>
<SUP>2</SUP> One study had inadequate allocation concealment &amp; no blinding &amp; one study had large loss to follow-up<BR/>
<SUP>3</SUP> 30% loss to follow-up in largest included study<BR/>
<SUP>4</SUP> Small numbers of patients and events<BR/>
<SUP>5</SUP> Small numbers of events</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-07-19 18:01:05 +1000" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-07-19 18:01:05 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2009-04-20 09:51:35 +1000" MODIFIED_BY="[Empty name]">Definition of kidney disease used in outcome assessment</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TH VALIGN="TOP">
<P>Study</P>
</TH>
<TH VALIGN="TOP">
<P>Timing of outcome</P>
</TH>
<TH VALIGN="TOP">
<P>Haematuria</P>
</TH>
<TH VALIGN="TOP">
<P>Proteinuria</P>
</TH>
<TH VALIGN="TOP">
<P>Blood pressure</P>
</TH>
<TH VALIGN="TOP">
<P>Kidney function</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Dudley-2013" TYPE="STUDY">Dudley 2013</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>1, 3 and 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>Any level on dipstick</P>
</TD>
<TD VALIGN="TOP">
<P>UPC &gt; 20 mg/mmol</P>
<P>Dipstick for protein</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Huber-2004" TYPE="STUDY">Huber 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>1, 3, 6 and 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>&#8805; 5 RBC/HPF or RBC casts</P>
</TD>
<TD VALIGN="TOP">
<P>&gt; 300 mg/L on dipstick</P>
</TD>
<TD VALIGN="TOP">
<P>&gt; 90th percentile for age and sex</P>
</TD>
<TD VALIGN="TOP">
<P>Elevated Cr</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Islek-1999" TYPE="STUDY">Islek 1999</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Mollica-1992" TYPE="STUDY">Mollica 1992</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>1, 3, 6 and 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>&#8805; 10 RBC/HPF</P>
</TD>
<TD VALIGN="TOP">
<P>&#8805; 4 mg/m²/h</P>
</TD>
<TD VALIGN="TOP">
<P>&gt; 2 SD above normal</P>
</TD>
<TD VALIGN="TOP">
<P>Cr &#8805; 0.8 mg/dL/mm²</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Peratoner-1990" TYPE="STUDY">Peratoner 1990</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>During initial 12 months</P>
</TD>
<TD VALIGN="TOP">
<P>&gt; 5 RBC/mm²</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Reduced GFR</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Ronkainen-2006a" TYPE="STUDY">Ronkainen 2006a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>1, 3 and 6 months</P>
</TD>
<TD VALIGN="TOP">
<P>&gt; 5 RBC/HPF</P>
</TD>
<TD VALIGN="TOP">
<P>&gt; 200 mg/L or urinary albumin &gt; 30 mg/L</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Jauhola-2010" TYPE="STUDY">Jauhola 2010</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>2 years</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Remission: UPC &lt; 200 mg/mmol or daily urine protein &lt; 40 mg/m²/d</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Tarshish-2004" TYPE="STUDY">Tarshish 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Mean follow-up to 7 years</P>
</TD>
<TD VALIGN="TOP">
<P>Addis Count &gt; 30,000 RBC/h/m² or &#8805; 1+ on dipstick &#8805; 3 cells/HPF or &gt; 2 RBC/mm³</P>
</TD>
<TD VALIGN="TOP">
<P>&gt; 4 mg/h/m² or 2+ or more by dipstick</P>
<P>Heavy proteinuria &gt; 40 mg/h/m²</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>GFR &lt; 80 mL/min/1.73 m²</P>
<P>ESKD</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-He-2002" TYPE="STUDY">He 2002</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yoshimoto-1987a" TYPE="STUDY">Yoshimoto 1987a</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Yoshimoto-1987b" TYPE="STUDY">Yoshimoto 1987b</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
<TD VALIGN="TOP">
<P>Not defined</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Cr - creatinine; ESKD - end-stage kidney disease; GFR - glomerular filtration rate; HPF - high power field; UPC - urinary protein:creatinine ratio; RBC - red blood cell</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2015-07-21 10:42:02 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Prednisone versus placebo/supportive treatment for preventing persistent kidney disease</NAME>
<DICH_OUTCOME CHI2="7.110031176186252" CI_END="1.3152655929606476" CI_START="0.41998023123839573" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7432264445453476" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="52" I2="43.741456248500455" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.11901345922161922" LOG_CI_START="-0.3767711516643317" LOG_EFFECT_SIZE="-0.12887884622135617" METHOD="MH" MODIFIED="2013-09-19 12:23:19 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.13018662395234892" P_Q="1.0" P_Z="0.3082113350727137" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="WEIGHT" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.16773882362146852" TOTALS="YES" TOTAL_1="382" TOTAL_2="364" WEIGHT="100.0" Z="1.0189824025055962">
<NAME>Persistent kidney disease at any time after treatment</NAME>
<GROUP_LABEL_1>Prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/supportive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/supportive</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0319745737416546" CI_START="0.00607570546004052" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.307918269284725" LOG_CI_START="-2.2164032881633746" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="24965" O_E="0.0" SE="1.4827989784382496" STUDY_ID="STD-Mollica-1992" TOTAL_1="84" TOTAL_2="84" VAR="2.1986928104575165" WEIGHT="3.5839944305895948"/>
<DICH_DATA CI_END="7.268192940288198" CI_START="0.25341054507296074" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8614264475009272" LOG_CI_START="-0.5961753169517453" LOG_EFFECT_SIZE="0.13262556527459096" ORDER="24964" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Huber-2004" TOTAL_1="21" TOTAL_2="19" VAR="0.7330827067669172" WEIGHT="9.415047832230927"/>
<DICH_DATA CI_END="1.12583222217763" CI_START="0.20750082162264918" EFFECT_SIZE="0.48333333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.05147367434166383" LOG_CI_START="-0.6829801793110388" LOG_EFFECT_SIZE="-0.31575325248468755" ORDER="24966" O_E="0.0" SE="0.4314218292408074" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="84" TOTAL_2="87" VAR="0.18612479474548438" WEIGHT="23.96764560327058"/>
<DICH_DATA CI_END="2.723386252032289" CI_START="0.7154548173972521" EFFECT_SIZE="1.3958724202626642" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.4351092407634229" LOG_CI_START="-0.1454177877248099" LOG_EFFECT_SIZE="0.14484572651930647" MODIFIED="2013-09-17 11:13:24 +1000" MODIFIED_BY="[Empty name]" ORDER="24963" O_E="0.0" SE="0.3410044501891247" STUDY_ID="STD-Dudley-2013" TOTAL_1="123" TOTAL_2="124" VAR="0.1162840350487872" WEIGHT="29.861250733894956"/>
<DICH_DATA CI_END="1.0644047247530917" CI_START="0.33286998994190314" EFFECT_SIZE="0.5952380952380952" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.027106793659924244" LOG_CI_START="-0.4777253571116499" LOG_EFFECT_SIZE="-0.22530928172586287" MODIFIED="2008-08-09 17:47:00 +1000" MODIFIED_BY="Elisabeth M Hodson" ORDER="53" O_E="0.0" SE="0.29654090432267166" STUDY_ID="STD-Islek-1999" TOTAL_1="70" TOTAL_2="50" VAR="0.08793650793650792" WEIGHT="33.172061400013945"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="24.846868627276365" CI_END="1.1093979090702395" CI_START="0.5171976539748739" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7574813501966622" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="168" I2="47.67952374598674" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.04508734301017491" LOG_CI_START="-0.2863434537608575" LOG_EFFECT_SIZE="-0.12062805537534131" METHOD="MH" MODIFIED="2013-10-10 12:35:27 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.024176366907855296" P_Q="0.6808930742804138" P_Z="0.15366554137762026" Q="1.5059704355654975" RANDOM="YES" SCALE="500.0" SORT_BY="WEIGHT" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.15858867917781713" TOTALS="SUB" TOTAL_1="1073" TOTAL_2="1071" WEIGHT="400.0" Z="1.4267029278157672">
<NAME>Number of children with any continuing kidney disease at different time points</NAME>
<GROUP_LABEL_1>Prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/supportive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/supportive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.776975714149177" CI_END="1.841936280263825" CI_START="0.3443703563985555" DF="3" EFFECT_SIZE="0.7964347137699882" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="64" I2="72.16287686292847" ID="CMP-001.02.01" LOG_CI_END="0.26527460218631105" LOG_CI_START="-0.4629742399321406" LOG_EFFECT_SIZE="-0.09884981887291479" MODIFIED="2013-10-02 17:11:54 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.01299508564529106" P_Z="0.5946729439180284" STUDIES="4" TAU2="0.42690022285193224" TOTAL_1="332" TOTAL_2="323" WEIGHT="100.0" Z="0.532076602567967">
<NAME>One month</NAME>
<DICH_DATA CI_END="0.7997455087934061" CI_START="0.00283536909080773" EFFECT_SIZE="0.047619047619047616" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="10" LOG_CI_END="-0.09704819014565919" LOG_CI_START="-2.5473903993221794" LOG_EFFECT_SIZE="-1.3222192947339193" ORDER="24969" O_E="0.0" SE="1.4393431430598436" STUDY_ID="STD-Mollica-1992" TOTAL_1="84" TOTAL_2="84" VAR="2.0717086834733895" WEIGHT="7.323800842270781"/>
<DICH_DATA CI_END="3.9550669145102075" CI_START="0.20697351574638634" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5971538355850753" LOG_CI_START="-0.6840852231472558" LOG_EFFECT_SIZE="-0.0434656937810903" ORDER="24968" O_E="0.0" SE="0.7526061653349982" STUDY_ID="STD-Huber-2004" TOTAL_1="21" TOTAL_2="19" VAR="0.5664160401002507" WEIGHT="18.422444789400952"/>
<DICH_DATA CI_END="1.2000563529061543" CI_START="0.3619836896778227" EFFECT_SIZE="0.6590909090909091" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="0.07920164036558065" LOG_CI_START="-0.4413109975400433" LOG_EFFECT_SIZE="-0.18105467858723137" ORDER="24970" O_E="0.0" SE="0.3057517000848757" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="84" TOTAL_2="87" VAR="0.09348410210479176" WEIGHT="35.16499851176814"/>
<DICH_DATA CI_END="2.244347912594675" CI_START="1.0123734479066286" EFFECT_SIZE="1.507354714251266" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="29" LOG_CI_END="0.35109018093000827" LOG_CI_START="0.00534074614756245" LOG_EFFECT_SIZE="0.17821546353878537" MODIFIED="2013-10-02 17:11:54 +1000" MODIFIED_BY="[Empty name]" ORDER="24967" O_E="0.0" SE="0.20309492947851335" STUDY_ID="STD-Dudley-2013" TOTAL_1="143" TOTAL_2="133" VAR="0.041247550379882314" WEIGHT="39.08875585656011"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.350859159799319" CI_END="1.5178945373664903" CI_START="0.4565227449281473" DF="3" EFFECT_SIZE="0.8324382143498642" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="66" I2="43.93423728027046" ID="CMP-001.02.02" LOG_CI_END="0.18124159802132644" LOG_CI_START="-0.34053758012155466" LOG_EFFECT_SIZE="-0.0796479910501141" MODIFIED="2013-10-10 12:35:27 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.14783611968704002" P_Z="0.5495964302030671" STUDIES="4" TAU2="0.15030640775191376" TOTAL_1="324" TOTAL_2="331" WEIGHT="100.0" Z="0.5983649805835859">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.3441160447786835" CI_START="0.004402268529044979" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="0.12843676531856899" LOG_CI_START="-2.3563234699322426" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="24973" O_E="0.0" SE="1.459560461947859" STUDY_ID="STD-Mollica-1992" TOTAL_1="84" TOTAL_2="84" VAR="2.130316742081448" WEIGHT="4.1190319854725"/>
<DICH_DATA CI_END="7.268192940288198" CI_START="0.25341054507296074" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8614264475009272" LOG_CI_START="-0.5961753169517453" LOG_EFFECT_SIZE="0.13262556527459096" ORDER="24972" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Huber-2004" TOTAL_1="21" TOTAL_2="19" VAR="0.7330827067669172" WEIGHT="10.633999838326524"/>
<DICH_DATA CI_END="1.258831796093567" CI_START="0.31823840510069584" EFFECT_SIZE="0.6329365079365079" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.0999677039691663" LOG_CI_START="-0.49724741074585466" LOG_EFFECT_SIZE="-0.1986398533883442" ORDER="24974" O_E="0.0" SE="0.3508071146460991" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="84" TOTAL_2="87" VAR="0.12306563168632133" WEIGHT="34.363279142507565"/>
<DICH_DATA CI_END="1.5766749401065174" CI_START="0.7627937421879281" EFFECT_SIZE="1.0966666666666667" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="40" LOG_CI_END="0.19774216493982755" LOG_CI_START="-0.11759287847920383" LOG_EFFECT_SIZE="0.04007464323031186" MODIFIED="2013-10-10 12:35:27 +1100" MODIFIED_BY="[Empty name]" ORDER="24971" O_E="0.0" SE="0.18522936543797833" STUDY_ID="STD-Dudley-2013" TOTAL_1="135" TOTAL_2="141" VAR="0.03430991782055612" WEIGHT="50.883689033693415"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8874574691318702" CI_END="1.1072885147842297" CI_START="0.23879121722026087" DF="2" EFFECT_SIZE="0.5142088799888047" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.044260795271861705" LOG_CI_START="-0.621981650670479" LOG_EFFECT_SIZE="-0.2888604276993087" NO="3" P_CHI2="0.3891740657038356" P_Z="0.08921568098216273" STUDIES="3" TAU2="0.0" TOTAL_1="189" TOTAL_2="190" WEIGHT="100.0" Z="1.6995495807797234">
<NAME>Six months</NAME>
<DICH_DATA CI_END="2.723684930083526" CI_START="0.007492850233848549" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4351568679103101" LOG_CI_START="-2.125352947938824" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="24976" O_E="0.0" SE="1.504056140557785" STUDY_ID="STD-Mollica-1992" TOTAL_1="84" TOTAL_2="84" VAR="2.26218487394958" WEIGHT="6.770359121633224"/>
<DICH_DATA CI_END="18.39201854331845" CI_START="0.17803246606790163" EFFECT_SIZE="1.8095238095238095" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2646293961286008" LOG_CI_START="-0.7495007923628191" LOG_EFFECT_SIZE="0.25756430188289087" ORDER="24975" O_E="0.0" SE="1.183110042825089" STUDY_ID="STD-Huber-2004" TOTAL_1="21" TOTAL_2="19" VAR="1.399749373433584" WEIGHT="10.941818790456459"/>
<DICH_DATA CI_END="1.12583222217763" CI_START="0.20750082162264918" EFFECT_SIZE="0.48333333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.05147367434166383" LOG_CI_START="-0.6829801793110388" LOG_EFFECT_SIZE="-0.31575325248468755" ORDER="24977" O_E="0.0" SE="0.4314218292408074" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="84" TOTAL_2="87" VAR="0.18612479474548438" WEIGHT="82.28782208791031"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.948239057389796" CI_END="2.9125642032801653" CI_START="0.38419993453689794" DF="2" EFFECT_SIZE="1.0578312607570035" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" I2="32.16289584838867" ID="CMP-001.02.04" LOG_CI_END="0.464275507535525" LOG_CI_START="-0.4154427134729363" LOG_EFFECT_SIZE="0.02441639703129427" MODIFIED="2013-10-02 17:18:07 +1000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.22898030556017956" P_Z="0.9133636707599907" STUDIES="3" TAU2="0.30374514451843654" TOTAL_1="228" TOTAL_2="227" WEIGHT="100.0" Z="0.10879678895069113">
<NAME>Twelve months</NAME>
<DICH_DATA CI_END="2.0319745737416546" CI_START="0.00607570546004052" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.307918269284725" LOG_CI_START="-2.2164032881633746" LOG_EFFECT_SIZE="-0.9542425094393249" ORDER="24980" O_E="0.0" SE="1.4827989784382496" STUDY_ID="STD-Mollica-1992" TOTAL_1="84" TOTAL_2="84" VAR="2.1986928104575165" WEIGHT="10.670851108549158"/>
<DICH_DATA CI_END="7.268192940288198" CI_START="0.25341054507296074" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8614264475009272" LOG_CI_START="-0.5961753169517453" LOG_EFFECT_SIZE="0.13262556527459096" ORDER="24979" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Huber-2004" TOTAL_1="21" TOTAL_2="19" VAR="0.7330827067669172" WEIGHT="25.754654249330585"/>
<DICH_DATA CI_END="2.723386252032289" CI_START="0.7154548173972521" EFFECT_SIZE="1.3958724202626642" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.4351092407634229" LOG_CI_START="-0.1454177877248099" LOG_EFFECT_SIZE="0.14484572651930647" MODIFIED="2013-10-02 17:18:07 +1000" MODIFIED_BY="[Empty name]" ORDER="24978" O_E="0.0" SE="0.3410044501891247" STUDY_ID="STD-Dudley-2013" TOTAL_1="123" TOTAL_2="124" VAR="0.1162840350487872" WEIGHT="63.57449464212026"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.014409683474108" CI_END="1.2998210172154971" CI_START="0.7777249927748313" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0054368658560797" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="145" I2="25.089952506118106" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.11388355493211492" LOG_CI_START="-0.10917394444234178" LOG_EFFECT_SIZE="0.0023548052448865817" METHOD="MH" MODIFIED="2015-07-18 19:13:20 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.2124982261270264" P_Q="0.5057611539027019" P_Z="0.9669909996554745" Q="2.3354640280402656" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04158543193089657" TOTALS="SUB" TOTAL_1="737" TOTAL_2="735" WEIGHT="399.99999999999994" Z="0.0413824550488283">
<NAME>Any continuing kidney disease at different time points (study with high risk of bias excluded)</NAME>
<GROUP_LABEL_1>Prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/supportive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/supportive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.198980815141288" CI_END="1.9325388514972914" CI_START="0.5386324732965799" DF="2" EFFECT_SIZE="1.020258879561319" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="54" I2="61.530921711130645" ID="CMP-001.03.01" LOG_CI_END="0.28612823367511286" LOG_CI_START="-0.26870746721046757" LOG_EFFECT_SIZE="0.008710383232322653" MODIFIED="2013-10-02 17:14:16 +1000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07431155034253101" P_Z="0.9509298973811022" STUDIES="3" TAU2="0.18288785959135598" TOTAL_1="248" TOTAL_2="239" WEIGHT="100.00000000000001" Z="0.06153907327753083">
<NAME>One month</NAME>
<DICH_DATA CI_END="2.244347912594675" CI_START="1.0123734479066286" EFFECT_SIZE="1.507354714251266" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="29" LOG_CI_END="0.35109018093000827" LOG_CI_START="0.00534074614756245" LOG_EFFECT_SIZE="0.17821546353878537" MODIFIED="2013-10-02 17:14:16 +1000" MODIFIED_BY="[Empty name]" ORDER="24981" O_E="0.0" SE="0.20309492947851335" STUDY_ID="STD-Dudley-2013" TOTAL_1="143" TOTAL_2="133" VAR="0.041247550379882314" WEIGHT="47.39074391840278"/>
<DICH_DATA CI_END="3.9550669145102075" CI_START="0.20697351574638634" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5971538355850753" LOG_CI_START="-0.6840852231472558" LOG_EFFECT_SIZE="-0.0434656937810903" ORDER="24982" O_E="0.0" SE="0.7526061653349982" STUDY_ID="STD-Huber-2004" TOTAL_1="21" TOTAL_2="19" VAR="0.5664160401002507" WEIGHT="14.175748746756662"/>
<DICH_DATA CI_END="1.2000563529061543" CI_START="0.3619836896778227" EFFECT_SIZE="0.6590909090909091" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="0.07920164036558065" LOG_CI_START="-0.4413109975400433" LOG_EFFECT_SIZE="-0.18105467858723137" ORDER="24983" O_E="0.0" SE="0.3057517000848757" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="84" TOTAL_2="87" VAR="0.09348410210479176" WEIGHT="38.43350733484058"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.078179626025552" CI_END="1.3637979812635175" CI_START="0.6992006076789566" DF="2" EFFECT_SIZE="0.976508257645979" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="60" I2="3.7619282301919075" ID="CMP-001.03.02" LOG_CI_END="0.13475004325279713" LOG_CI_START="-0.15539820292585166" LOG_EFFECT_SIZE="-0.010324079836527259" MODIFIED="2013-10-02 17:15:17 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.35377669610059914" P_Z="0.8890714802748867" STUDIES="3" TAU2="0.005249898925828852" TOTAL_1="240" TOTAL_2="247" WEIGHT="99.99999999999997" Z="0.13947921395086224">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.5766749401065174" CI_START="0.7627937421879281" EFFECT_SIZE="1.0966666666666667" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="40" LOG_CI_END="0.19774216493982755" LOG_CI_START="-0.11759287847920383" LOG_EFFECT_SIZE="0.04007464323031186" MODIFIED="2013-10-02 17:15:17 +1000" MODIFIED_BY="[Empty name]" ORDER="24984" O_E="0.0" SE="0.18522936543797833" STUDY_ID="STD-Dudley-2013" TOTAL_1="135" TOTAL_2="141" VAR="0.03430991782055612" WEIGHT="73.4278534494269"/>
<DICH_DATA CI_END="7.268192940288198" CI_START="0.25341054507296074" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8614264475009272" LOG_CI_START="-0.5961753169517453" LOG_EFFECT_SIZE="0.13262556527459096" ORDER="24985" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Huber-2004" TOTAL_1="21" TOTAL_2="19" VAR="0.7330827067669172" WEIGHT="3.934259985463187"/>
<DICH_DATA CI_END="1.258831796093567" CI_START="0.31823840510069584" EFFECT_SIZE="0.6329365079365079" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.0999677039691663" LOG_CI_START="-0.49724741074585466" LOG_EFFECT_SIZE="-0.1986398533883442" ORDER="24986" O_E="0.0" SE="0.3508071146460991" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="84" TOTAL_2="87" VAR="0.12306563168632133" WEIGHT="22.637886565109884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0998680361373396" CI_END="1.4968386175861808" CI_START="0.23320095242675962" DF="1" EFFECT_SIZE="0.5908165461886216" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="9.08000167802578" ID="CMP-001.03.03" LOG_CI_END="0.17517497918746025" LOG_CI_START="-0.6322696801872884" LOG_EFFECT_SIZE="-0.228547350499914" NO="3" P_CHI2="0.2942955622839677" P_Z="0.2671989159968109" STUDIES="2" TAU2="0.07918906936849034" TOTAL_1="105" TOTAL_2="106" WEIGHT="100.0" Z="1.1095362896789815">
<NAME>Six months</NAME>
<DICH_DATA CI_END="18.39201854331845" CI_START="0.17803246606790163" EFFECT_SIZE="1.8095238095238095" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2646293961286008" LOG_CI_START="-0.7495007923628191" LOG_EFFECT_SIZE="0.25756430188289087" ORDER="24987" O_E="0.0" SE="1.183110042825089" STUDY_ID="STD-Huber-2004" TOTAL_1="21" TOTAL_2="19" VAR="1.399749373433584" WEIGHT="15.210750363464722"/>
<DICH_DATA CI_END="1.12583222217763" CI_START="0.20750082162264918" EFFECT_SIZE="0.48333333333333334" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.05147367434166383" LOG_CI_START="-0.6829801793110388" LOG_EFFECT_SIZE="-0.31575325248468755" ORDER="24988" O_E="0.0" SE="0.4314218292408074" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="84" TOTAL_2="87" VAR="0.18612479474548438" WEIGHT="84.78924963653527"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.321664951084587E-4" CI_END="2.5872337760795663" CI_START="0.7473253871671697" DF="1" EFFECT_SIZE="1.390505477659344" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.412835672270592" LOG_CI_START="-0.1264902642053074" LOG_EFFECT_SIZE="0.1431727040326423" MODIFIED="2013-10-10 12:38:03 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9756432514546278" P_Z="0.2980577014677872" STUDIES="2" TAU2="0.0" TOTAL_1="144" TOTAL_2="143" WEIGHT="99.99999999999999" Z="1.0406076344364021">
<NAME>Twelve months</NAME>
<DICH_DATA CI_END="2.723386252032289" CI_START="0.7154548173972521" EFFECT_SIZE="1.3958724202626642" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.4351092407634229" LOG_CI_START="-0.1454177877248099" LOG_EFFECT_SIZE="0.14484572651930647" MODIFIED="2013-10-10 12:38:03 +1100" MODIFIED_BY="[Empty name]" ORDER="24989" O_E="0.0" SE="0.3410044501891247" STUDY_ID="STD-Dudley-2013" TOTAL_1="123" TOTAL_2="124" VAR="0.1162840350487872" WEIGHT="86.30932560413125"/>
<DICH_DATA CI_END="7.268192940288198" CI_START="0.25341054507296074" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8614264475009272" LOG_CI_START="-0.5961753169517453" LOG_EFFECT_SIZE="0.13262556527459096" ORDER="24990" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Huber-2004" TOTAL_1="21" TOTAL_2="19" VAR="0.7330827067669172" WEIGHT="13.690674395868738"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="32" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-18 19:13:36 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="108" TOTAL_2="105" WEIGHT="0.0" Z="0.0">
<NAME>Number of children with kidney disease in first month/with kidney disease at follow-up</NAME>
<GROUP_LABEL_1>Prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/supportive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/supportive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="22" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>One month</NAME>
<DICH_DATA CI_END="1.002068620454207" CI_START="0.38198326309436104" EFFECT_SIZE="0.6186868686868687" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="8.974625134620644E-4" LOG_CI_START="-0.41795566563542164" LOG_EFFECT_SIZE="-0.2085291015609798" ORDER="24991" O_E="0.0" SE="0.2460364008310773" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="36" TOTAL_2="35" VAR="0.06053391053391054" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="18" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Three months</NAME>
<DICH_DATA CI_END="1.070064374662473" CI_START="0.3298842201778643" EFFECT_SIZE="0.5941358024691358" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.029409905460640907" LOG_CI_START="-0.4816384581848263" LOG_EFFECT_SIZE="-0.22611427636209266" ORDER="24992" O_E="0.0" SE="0.30019233853554644" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="36" TOTAL_2="35" VAR="0.09011544011544012" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="15" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="35" WEIGHT="0.0" Z="0.0">
<NAME>Six months</NAME>
<DICH_DATA CI_END="0.9770382352403751" CI_START="0.21068474429131714" EFFECT_SIZE="0.4537037037037037" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="-0.010088440345720841" LOG_CI_START="-0.6763669105711512" LOG_EFFECT_SIZE="-0.343227675458436" ORDER="24993" O_E="0.0" SE="0.39137527154203694" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="36" TOTAL_2="35" VAR="0.15317460317460313" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19243310916148432" CI_END="6.0019565147261575" CI_START="0.41764800041901295" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.583257760750677" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.7782928445571964" LOG_CI_START="-0.37918959353279735" LOG_EFFECT_SIZE="0.19955162551219954" METHOD="MH" MODIFIED="2015-07-18 19:13:55 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.660899238453114" P_Q="1.0" P_Z="0.4991668895335055" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="207" TOTAL_2="211" WEIGHT="100.00000000000001" Z="0.6758011805444368">
<NAME>Number developing severe kidney disease</NAME>
<GROUP_LABEL_1>Prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/supportive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/supportive</GRAPH_LABEL_2>
<DICH_DATA CI_END="73.5229160928985" CI_START="0.12439314303788228" EFFECT_SIZE="3.024193548387097" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8664227238668898" LOG_CI_START="-0.9052035587359222" LOG_EFFECT_SIZE="0.4806095825654838" MODIFIED="2013-09-30 15:26:20 +1000" MODIFIED_BY="[Empty name]" ORDER="24994" O_E="0.0" SE="1.6280669981722602" STUDY_ID="STD-Dudley-2013" TOTAL_1="123" TOTAL_2="124" VAR="2.650602150537634" WEIGHT="17.440521979594774"/>
<DICH_DATA CI_END="5.985800734713489" CI_START="0.3185922089585445" EFFECT_SIZE="1.380952380952381" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7771222552280631" LOG_CI_START="-0.49676484889798966" LOG_EFFECT_SIZE="0.1401787031650368" ORDER="24995" O_E="0.0" SE="0.7482875908065082" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="84" TOTAL_2="87" VAR="0.5599343185550082" WEIGHT="82.55947802040524"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2015-07-21 10:32:59 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="30" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Duration of kidney disease</NAME>
<GROUP_LABEL_1>Prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/supportive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/supportive</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Haematuria</NAME>
<CONT_DATA CI_END="8.255306058832323" CI_START="-10.255306058832323" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="12.2" MEAN_2="13.2" ORDER="24996" SD_1="15.9" SD_2="9.9" SE="4.722181699172534" STUDY_ID="STD-Islek-1999" TOTAL_1="15" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<CONT_DATA CI_END="12.415043893851413" CI_START="-15.615043893851412" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="10.6" ORDER="24997" SD_1="15.06" SD_2="25.46" SE="7.1506639940326915" STUDY_ID="STD-Islek-1999" TOTAL_1="15" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.04173067079261447" CI_END="1.2283624622203517" CI_START="0.2543595883473517" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5589684876911292" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.08932653627993997" LOG_CI_START="-0.5945518865450773" LOG_EFFECT_SIZE="-0.25261267513256863" METHOD="MH" MODIFIED="2015-07-18 19:14:37 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.9793508473493235" P_Q="1.0" P_Z="0.14763032779937973" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="261" TOTAL_2="256" WEIGHT="100.0" Z="1.447952527155064">
<NAME>Gastrointestinal complications requiring hospital admission</NAME>
<GROUP_LABEL_1>Prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/supportive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/supportive</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.58609231227648" CI_START="0.08937772722079332" EFFECT_SIZE="0.4807692307692308" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4126440232500003" LOG_CI_START="-1.0487706931755234" LOG_EFFECT_SIZE="-0.3180633349627615" MODIFIED="2013-10-24 13:19:42 +1100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.8584422385478693" STUDY_ID="STD-Dudley-2013" TOTAL_1="156" TOTAL_2="150" VAR="0.7369230769230769" WEIGHT="21.898322638356532"/>
<DICH_DATA CI_END="3.2303079734614215" CI_START="0.11262690892131588" EFFECT_SIZE="0.6031746031746031" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5092439293895648" LOG_CI_START="-0.9483578350631079" LOG_EFFECT_SIZE="-0.21955695283677157" ORDER="24998" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Huber-2004" TOTAL_1="21" TOTAL_2="19" VAR="0.7330827067669172" WEIGHT="22.01304047845017"/>
<DICH_DATA CI_END="1.6464242820026187" CI_START="0.20109124379168877" EFFECT_SIZE="0.5753968253968254" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.21654176258234092" LOG_CI_START="-0.6966068396754793" LOG_EFFECT_SIZE="-0.24003253854656925" ORDER="24999" O_E="0.0" SE="0.536388009124725" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="84" TOTAL_2="87" VAR="0.287712096332786" WEIGHT="56.0886368831933"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-21 10:42:02 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="350" TOTAL_2="340" WEIGHT="0.0" Z="0.0">
<NAME>Eight-year outcomes</NAME>
<GROUP_LABEL_1>Prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/supportive</GROUP_LABEL_2>
<GRAPH_LABEL_1>Prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo/supportive</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-10-30 15:28:28 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Haematuria</NAME>
<DICH_DATA CI_END="99.39444968306866" CI_START="0.2375523653979146" EFFECT_SIZE="4.859154929577465" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.997362133498754" LOG_CI_START="-0.6242406407903565" LOG_EFFECT_SIZE="0.6865607463541988" MODIFIED="2013-10-30 10:18:09 +1100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="1.5399424467604488" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="70" TOTAL_2="68" VAR="2.371422739334558" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-10-30 15:28:28 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<DICH_DATA CI_END="70.34775658548246" CI_START="0.12082971226439174" EFFECT_SIZE="2.915492957746479" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8472502521889471" LOG_CI_START="-0.9178262587132621" LOG_EFFECT_SIZE="0.46471199673784247" MODIFIED="2013-10-30 10:18:40 +1100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="1.6242196298534335" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="70" TOTAL_2="68" VAR="2.6380894060012245" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 18:53:46 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Haematuria and proteinuria</NAME>
<DICH_DATA CI_END="70.34775658548246" CI_START="0.12082971226439174" EFFECT_SIZE="2.915492957746479" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8472502521889471" LOG_CI_START="-0.9178262587132621" LOG_EFFECT_SIZE="0.46471199673784247" MODIFIED="2013-10-30 10:19:00 +1100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="1.6242196298534335" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="70" TOTAL_2="68" VAR="2.6380894060012245" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-10-30 15:28:28 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Hypertension</NAME>
<DICH_DATA CI_END="6.701666608498107" CI_START="0.14081175989732486" EFFECT_SIZE="0.9714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8261828189497149" LOG_CI_START="-0.8513610735657561" LOG_EFFECT_SIZE="-0.012589127308020516" MODIFIED="2013-10-30 10:19:19 +1100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.9853975864397805" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="70" TOTAL_2="68" VAR="0.9710084033613446" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.08.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-10-30 15:28:28 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Decreased GFR (Schwartz formula)</NAME>
<DICH_DATA CI_END="99.39444968306866" CI_START="0.2375523653979146" EFFECT_SIZE="4.859154929577465" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.997362133498754" LOG_CI_START="-0.6242406407903565" LOG_EFFECT_SIZE="0.6865607463541988" MODIFIED="2013-10-30 10:20:19 +1100" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="1.5399424467604488" STUDY_ID="STD-Ronkainen-2006a" TOTAL_1="70" TOTAL_2="68" VAR="2.371422739334558" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-07-21 10:57:11 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Antiplatelet agents versus supportive treatment for preventing persistent kidney disease</NAME>
<DICH_OUTCOME CHI2="0.3609580428370557" CI_END="2.346235947409349" CI_START="0.49771271994891736" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0806255017474982" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.37037168446548036" LOG_CI_START="-0.3030212599330237" LOG_EFFECT_SIZE="0.03367521226622836" METHOD="MH" MODIFIED="2015-07-21 10:57:11 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.8348702360351328" P_Q="0.7899437791236816" P_Z="0.8445876293687817" Q="0.07096023673439847" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="70" TOTAL_2="50" WEIGHT="200.0" Z="0.19602879347809116">
<NAME>Kidney disease at any time</NAME>
<GROUP_LABEL_1>Antiplatelet agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Supportive treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Antiplatelet agents</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Supportive treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2873237278802378" CI_END="2.9464921663966344" CI_START="0.45629166963894696" DF="1" EFFECT_SIZE="1.1595084433427807" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.46930529080865396" LOG_CI_START="-0.3407574599208788" LOG_EFFECT_SIZE="0.06427391544388764" MODIFIED="2013-10-30 10:53:36 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5919407461124231" P_Z="0.7557822250717955" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="44" WEIGHT="100.0" Z="0.31102419979672274">
<NAME>Dipyridamole ± cyproheptadine in children without kidney disease at entry</NAME>
<DICH_DATA CI_END="5.5475336927985435" CI_START="0.3998530522931521" EFFECT_SIZE="1.4893617021276595" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.7440999485880571" LOG_CI_START="-0.39809958443097837" LOG_EFFECT_SIZE="0.17300018207853934" ORDER="25000" O_E="0.0" SE="0.6709336596742561" STUDY_ID="STD-Peratoner-1990" TOTAL_1="47" TOTAL_2="35" VAR="0.4501519756838906" WEIGHT="50.29830710716682"/>
<DICH_DATA CI_END="3.3787788217510375" CI_START="0.23973158431844938" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.5287597633531887" LOG_CI_START="-0.620274744474539" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2013-10-30 10:53:36 +1100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.6749485577105528" STUDY_ID="STD-Yoshimoto-1987b" TOTAL_1="10" TOTAL_2="9" VAR="0.45555555555555555" WEIGHT="49.70169289283317"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7236963680632966" CI_START="0.22882397534477927" DF="0" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.5709742611786154" LOG_CI_START="-0.6404984736970393" LOG_EFFECT_SIZE="-0.03476210625921192" MODIFIED="2009-04-20 09:31:01 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.910443808896551" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="6" WEIGHT="100.0" Z="0.11247876131822786">
<NAME>Dipyridamole ± cyproheptadine in children with kidney disease at entry</NAME>
<DICH_DATA CI_END="3.7236963680632966" CI_START="0.22882397534477927" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.5709742611786154" LOG_CI_START="-0.6404984736970393" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="55" O_E="0.0" SE="0.7116250813527137" STUDY_ID="STD-Peratoner-1990" TOTAL_1="13" TOTAL_2="6" VAR="0.5064102564102565" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-21 10:57:11 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="200.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Kidney disease at any time</NAME>
<GROUP_LABEL_1>Antiplatelet agents</GROUP_LABEL_1>
<GROUP_LABEL_2>Supportive treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Antiplatelet agents</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Supportive treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 18:54:31 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Aspirin versus supportive treatment</NAME>
<DICH_DATA CI_END="2.4221856060490086" CI_START="0.008425515870600543" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.3842074189864019" LOG_CI_START="-2.074403499014916" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="56" O_E="0.0" SE="1.4442002235542983" STUDY_ID="STD-Yoshimoto-1987a" TOTAL_1="9" TOTAL_2="9" VAR="2.0857142857142854" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Heparin versus placebo for preventing persistent kidney disease</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-18 19:18:48 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="119" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Any kidney disease at 3 months after onset or relapse</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5523124567127617" CI_START="0.1367151817763249" EFFECT_SIZE="0.2747899159663866" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="30" LOG_CI_END="-0.25781516170008156" LOG_CI_START="-0.8641832557644077" LOG_EFFECT_SIZE="-0.5609992087322446" ORDER="25005" O_E="0.0" SE="0.3561836200238595" STUDY_ID="STD-He-2002" TOTAL_1="119" TOTAL_2="109" VAR="0.1268667711733011" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-18 19:19:06 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="357" TOTAL_2="327" WEIGHT="0.0" Z="0.0">
<NAME>Type of kidney disease at 3 months or more after onset or relapse</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Heparin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="12" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Haematuria</NAME>
<DICH_DATA CI_END="0.6667672496657898" CI_START="0.034952827397102634" EFFECT_SIZE="0.15266106442577032" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.1760257400358929" LOG_CI_START="-1.4565176876352086" LOG_EFFECT_SIZE="-0.8162717138355507" ORDER="25006" O_E="0.0" SE="0.7521673085572053" STUDY_ID="STD-He-2002" TOTAL_1="119" TOTAL_2="109" VAR="0.56575566006219" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="15" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<DICH_DATA CI_END="0.9105806958854394" CI_START="0.1474214290004646" EFFECT_SIZE="0.3663865546218487" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.040681560879681666" LOG_CI_START="-0.8314393833682078" LOG_EFFECT_SIZE="-0.4360604721239448" ORDER="25007" O_E="0.0" SE="0.46449505924411083" STUDY_ID="STD-He-2002" TOTAL_1="119" TOTAL_2="109" VAR="0.21575566006219002" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="109" WEIGHT="0.0" Z="0.0">
<NAME>Nephrotic syndrome</NAME>
<DICH_DATA CI_END="2.891617666413583" CI_START="0.03223856440262302" EFFECT_SIZE="0.30532212885154064" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46114086941650617" LOG_CI_START="-1.4916243057596452" LOG_EFFECT_SIZE="-0.5152417181715695" ORDER="25008" O_E="0.0" SE="1.1470639302419852" STUDY_ID="STD-He-2002" TOTAL_1="119" TOTAL_2="109" VAR="1.31575566006219" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="60.36186037383735" CI_START="34.23813962616264" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="47.3" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="1.27051924844295E-12" Q="0.0" RANDOM="YES" SCALE="101.52" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="119" TOTAL_2="109" UNITS="" WEIGHT="0.0" Z="7.097480283469682">
<NAME>Time to development of kidney disease</NAME>
<GROUP_LABEL_1>Heparin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Longer with placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Longer with heparin</GRAPH_LABEL_2>
<CONT_DATA CI_END="60.36186037383735" CI_START="34.23813962616264" EFFECT_SIZE="47.3" ESTIMABLE="YES" MEAN_1="81.8" MEAN_2="34.5" ORDER="25009" SD_1="64.5" SD_2="32.1" SE="6.664336935202709" STUDY_ID="STD-He-2002" TOTAL_1="119" TOTAL_2="109" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-07-21 10:56:46 +1000" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Cyclophosphamide versus supportive treatment for treating severe kidney disease</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.777225421534967" CI_START="0.6459277308119932" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.2497425167865892" LOG_CI_START="-0.18981607003170284" LOG_EFFECT_SIZE="0.029963223377443202" METHOD="MH" MODIFIED="2015-07-18 19:21:18 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.7893088306840483" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0" Z="0.2672082422759914">
<NAME>Persistent kidney disease</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Supportive treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Supportive treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.777225421534967" CI_START="0.6459277308119932" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.2497425167865892" LOG_CI_START="-0.18981607003170284" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="24958" O_E="0.0" SE="0.25819888974716115" STUDY_ID="STD-Tarshish-2004" TOTAL_1="28" TOTAL_2="28" VAR="0.06666666666666668" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.085752706571519" CI_START="0.3670737176021722" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.875" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.31926281581731847" LOG_CI_START="-0.4352467097726919" LOG_EFFECT_SIZE="-0.057991946977686754" METHOD="MH" MODIFIED="2015-07-21 10:56:46 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.7631953064327713" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0" Z="0.30128745526636297">
<NAME>Persistent severe kidney disease</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Supportive treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Supportive treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.085752706571519" CI_START="0.3670737176021722" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.31926281581731847" LOG_CI_START="-0.4352467097726919" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="24959" O_E="0.0" SE="0.44320263021395917" STUDY_ID="STD-Tarshish-2004" TOTAL_1="28" TOTAL_2="28" VAR="0.19642857142857145" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.048420389879559" CI_START="0.18452179426021492" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.75" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.4840748578170289" LOG_CI_START="-0.7339523310336287" LOG_EFFECT_SIZE="-0.12493873660829995" METHOD="MH" MODIFIED="2015-07-18 19:22:13 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.6876212394832732" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="28" TOTAL_2="28" WEIGHT="0.0" Z="0.4020853167609021">
<NAME>ESKD</NAME>
<GROUP_LABEL_1>CPA</GROUP_LABEL_1>
<GROUP_LABEL_2>Supportive treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>CPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Supportive treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.048420389879559" CI_START="0.18452179426021492" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4840748578170289" LOG_CI_START="-0.7339523310336287" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="24960" O_E="0.0" SE="0.7154752000627009" STUDY_ID="STD-Tarshish-2004" TOTAL_1="28" TOTAL_2="28" VAR="0.5119047619047619" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2015-07-18 19:29:27 +1000" MODIFIED_BY="Narelle S Willis" NO="5">
<NAME>Cyclophosphamide + steroids versus steroids</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-18 19:22:50 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="50" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>Primary outcome: BVAS at 6 months</NAME>
<GROUP_LABEL_1>CPA + prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Prednisone</GROUP_LABEL_2>
<GRAPH_LABEL_1>CPA + prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Prednisone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 19:10:42 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>BVAS = 0 at 6 months</NAME>
<DICH_DATA CI_END="5.241882160900927" CI_START="0.25670168819070327" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7194872536487901" LOG_CI_START="-0.5905712751949532" LOG_EFFECT_SIZE="0.06445798922691845" MODIFIED="2013-10-02 17:26:44 +1000" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.7695348647371196" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="25" TOTAL_2="29" VAR="0.592183908045977" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="22" EVENTS_2="26" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-10-02 17:27:32 +1000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Improvement in BVAS score</NAME>
<DICH_DATA CI_END="1.1873548578892306" CI_START="0.8113983322491852" EFFECT_SIZE="0.9815384615384616" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" LOG_CI_END="0.07458053343770275" LOG_CI_START="-0.09076588928108922" LOG_EFFECT_SIZE="-0.008092677921693232" MODIFIED="2013-09-30 14:57:42 +1000" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.09712530718301109" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="25" TOTAL_2="29" VAR="0.009433325295394264" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="36" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-18 19:23:13 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="129" TOTAL_2="149" WEIGHT="0.0" Z="0.0">
<NAME>Secondary endpoints at 12 months</NAME>
<GROUP_LABEL_1>CPA + prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Prednisone</GROUP_LABEL_2>
<GRAPH_LABEL_1>CPA + prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Prednisone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 19:10:18 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>BP &gt; 125/75 mm Hg</NAME>
<DICH_DATA CI_END="1.4324503030200706" CI_START="0.7394211342234167" EFFECT_SIZE="1.0291666666666666" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.15607956362473627" LOG_CI_START="-0.13110814052861694" LOG_EFFECT_SIZE="0.012485711548059664" MODIFIED="2013-09-30 15:07:40 +1000" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.16869547902174248" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="16" TOTAL_2="19" VAR="0.02845816464237516" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 18:56:30 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>eGFR &lt; 60 mL/min</NAME>
<DICH_DATA CI_END="1.9257474497134954" CI_START="0.32545083271659225" EFFECT_SIZE="0.7916666666666666" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.2845993313931186" LOG_CI_START="-0.48751461291067283" LOG_EFFECT_SIZE="-0.10145764075877708" MODIFIED="2013-09-30 15:08:59 +1000" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.4535435529097122" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="15" TOTAL_2="19" VAR="0.20570175438596494" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-005.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 18:56:40 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria &gt; 1 g/d</NAME>
<DICH_DATA CI_END="2.792959366195577" CI_START="0.20139927805903177" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4460646173460429" LOG_CI_START="-0.6959420905626427" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-09-30 15:09:36 +1000" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="15" TOTAL_2="15" VAR="0.44999999999999996" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="14" I2="0.0" ID="CMP-005.02.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 19:10:08 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>RAS blockers</NAME>
<DICH_DATA CI_END="1.4404406121153022" CI_START="0.637118803012708" EFFECT_SIZE="0.957983193277311" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.15849535747079194" LOG_CI_START="-0.19577957758290826" LOG_EFFECT_SIZE="-0.018642110056058148" MODIFIED="2013-09-30 15:10:18 +1000" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.20810285053975508" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="17" TOTAL_2="19" VAR="0.043306796402771644" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="4" I2="0.0" ID="CMP-005.02.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 18:57:16 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Kidney function improvement &gt; 50%</NAME>
<DICH_DATA CI_END="2.3953024641445833" CI_START="0.03679483778950435" EFFECT_SIZE="0.296875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.37936036126416967" LOG_CI_START="-1.434213107326286" LOG_EFFECT_SIZE="-0.5274263730310582" MODIFIED="2013-10-16 16:54:47 +1100" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="1.065302032783488" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="16" TOTAL_2="19" VAR="1.1348684210526316" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-005.02.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 18:57:23 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>ESKD</NAME>
<DICH_DATA CI_END="17.603979554200347" CI_START="0.07643726214615698" EFFECT_SIZE="1.16" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2456108554883214" LOG_CI_START="-1.1166948770344847" LOG_EFFECT_SIZE="0.06445798922691845" MODIFIED="2013-10-16 16:53:21 +1100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="1.3876300808858644" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="25" TOTAL_2="29" VAR="1.9255172413793102" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-005.02.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-12-12 12:52:17 +1100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Mortality</NAME>
<DICH_DATA CI_END="1.4992603933202662" CI_START="0.024930811181505863" EFFECT_SIZE="0.19333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.17587706817914822" LOG_CI_START="-1.6032635904925987" LOG_EFFECT_SIZE="-0.7136932611567252" MODIFIED="2013-12-12 12:52:17 +1100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="1.0450760297920803" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="25" TOTAL_2="29" VAR="1.092183908045977" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-18 19:23:40 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="125" TOTAL_2="145" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>CPA + prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>Prednisone</GROUP_LABEL_2>
<GRAPH_LABEL_1>CPA + prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Prednisone</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-07 16:57:33 +1100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>infection</NAME>
<DICH_DATA CI_END="0.1819598008174373" CI_START="-0.3116149732312304" EFFECT_SIZE="-0.06482758620689655" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-07 16:57:33 +1100" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.12591424585908784" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="25" TOTAL_2="29" VAR="0.01585439731026282" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-07 16:58:05 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Newly diagnosed or deterioration in existing diabetes</NAME>
<DICH_DATA CI_END="0.22727652626613262" CI_START="-0.23003514695578783" EFFECT_SIZE="-0.0013793103448276056" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-07 16:58:05 +1100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.11666328484327686" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="25" TOTAL_2="29" VAR="0.013610322030423552" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-005.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-07 16:58:47 +1100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Depression/anxiety</NAME>
<DICH_DATA CI_END="0.1517991032203837" CI_START="-0.1297301377031423" EFFECT_SIZE="0.011034482758620692" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-07 16:58:47 +1100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.07182000361848297" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="25" TOTAL_2="29" VAR="0.005158112919758907" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-005.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-07 17:00:26 +1100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Alopecia</NAME>
<DICH_DATA CI_END="0.10705886041281329" CI_START="-0.09602437765419261" EFFECT_SIZE="0.005517241379310346" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-07 17:00:13 +1100" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="0.05180790046880977" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="25" TOTAL_2="29" VAR="0.0026840585509861" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-005.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-07 17:00:32 +1100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="0.0229748131670708" CI_START="-0.22987136489120874" EFFECT_SIZE="-0.10344827586206896" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-01-07 16:59:19 +1100" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.06450276128865068" STUDY_ID="STD-CESAR-Study-2010" TOTAL_1="25" TOTAL_2="29" VAR="0.004160606213860652" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2015-07-18 19:25:45 +1000" MODIFIED_BY="Narelle S Willis" NO="6">
<NAME>Cyclosporin versus methylprednisolone for treating severe kidney disease</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.6913292729569904" CI_START="0.9524008128334105" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.875" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.5671827867426861" LOG_CI_START="-0.02118024261521083" LOG_EFFECT_SIZE="0.27300127206373764" METHOD="MH" MODIFIED="2015-07-18 19:25:37 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.06893399979180824" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0" Z="1.8188520837636308">
<NAME>Number with remission at 3 months</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Methylprednisolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Methylprednisolone</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6913292729569904" CI_START="0.9524008128334105" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.5671827867426861" LOG_CI_START="-0.02118024261521083" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2013-10-17 13:02:26 +1100" MODIFIED_BY="[Empty name]" ORDER="24961" O_E="0.0" SE="0.3456073558887953" STUDY_ID="STD-Jauhola-2010" TOTAL_1="7" TOTAL_2="8" VAR="0.11944444444444441" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5394504003496063" CI_START="0.7406391265888399" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3714285714285714" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.40473973476066566" LOG_CI_START="-0.1303933487100425" LOG_EFFECT_SIZE="0.13717319302531158" METHOD="MH" MODIFIED="2015-07-18 19:25:45 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.31498659521934735" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0" Z="1.0048136670237773">
<NAME>Number with remission at last follow-up (mean 6.3 years)</NAME>
<GROUP_LABEL_1>CSA</GROUP_LABEL_1>
<GROUP_LABEL_2>Methylprednisolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>CSA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Methylprednisolone</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5394504003496063" CI_START="0.7406391265888399" EFFECT_SIZE="1.3714285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.40473973476066566" LOG_CI_START="-0.1303933487100425" LOG_EFFECT_SIZE="0.13717319302531158" MODIFIED="2013-10-17 13:13:58 +1100" MODIFIED_BY="[Empty name]" ORDER="24962" O_E="0.0" SE="0.3143398221821789" STUDY_ID="STD-Jauhola-2010" TOTAL_1="7" TOTAL_2="8" VAR="0.09880952380952385" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2015-07-18 19:25:19 +1000" MODIFIED_BY="Narelle S Willis" NO="7">
<NAME>Mycophenolate mofetil versus azathioprine for treating severe kidney disease</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-18 19:25:19 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Remission of proteinuria at 1 year</NAME>
<GROUP_LABEL_1>MMF/prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>AZA/prednisone</GROUP_LABEL_2>
<GRAPH_LABEL_1>AZA/prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>MMF/prednisone</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0208690706957286" CI_START="0.8561844562225203" EFFECT_SIZE="1.3153846153846154" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.3055381770896109" LOG_CI_START="-0.06743266091897686" LOG_EFFECT_SIZE="0.11905275808531707" MODIFIED="2014-01-08 16:55:27 +1100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.2190849164816683" STUDY_ID="STD-Fuentes-2010" TOTAL_1="9" TOTAL_2="8" VAR="0.04799820062977958" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-18 19:25:10 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="9" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Regression of histological lesions at 1 year</NAME>
<GROUP_LABEL_1>MMF/prednisone</GROUP_LABEL_1>
<GROUP_LABEL_2>AZA/prednisone</GROUP_LABEL_2>
<GRAPH_LABEL_1>AZA/prednisone</GRAPH_LABEL_1>
<GRAPH_LABEL_2>MMF/prednisone</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3609140514571423" CI_START="0.6559501708047479" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.37308017697397367" LOG_CI_START="-0.18312915051226022" LOG_EFFECT_SIZE="0.09497551323085675" MODIFIED="2014-01-08 16:54:40 +1100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.3267201122459892" STUDY_ID="STD-Fuentes-2010" TOTAL_1="9" TOTAL_2="8" VAR="0.10674603174603176" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2015-07-18 19:29:17 +1000" MODIFIED_BY="Narelle S Willis" NO="8">
<NAME>Fosinopril + supportive treatment versus supportive treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-07-18 19:27:00 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="WEIGHT" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="81" TOTAL_2="63" WEIGHT="0.0" Z="0.0">
<NAME>Proteinuria</NAME>
<GROUP_LABEL_1>Fosinopril</GROUP_LABEL_1>
<GROUP_LABEL_2>Supportive treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Supportive treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Fosinopril</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="2" I2="0.0" ID="CMP-008.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 18:59:27 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Complete remission of proteinuria &lt; 150 mg/d</NAME>
<DICH_DATA CI_END="22.744706424181793" CI_START="1.49607460932536" EFFECT_SIZE="5.833333333333333" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="2" LOG_CI_END="1.3568803355743846" LOG_CI_START="0.17495325235887957" LOG_EFFECT_SIZE="0.7659167939666319" MODIFIED="2014-01-21 20:43:22 +1100" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.6942698193142073" STUDY_ID="STD-Xu-2009" TOTAL_1="27" TOTAL_2="21" VAR="0.48201058201058206" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="9" I2="0.0" ID="CMP-008.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-22 16:29:47 +1100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Partial remission</NAME>
<DICH_DATA CI_END="1.0981123624563633" CI_START="0.1700275395045134" EFFECT_SIZE="0.43209876543209874" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.040646780822707604" LOG_CI_START="-0.7694807298794559" LOG_EFFECT_SIZE="-0.3644169745283741" MODIFIED="2014-01-17 15:32:15 +1100" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.47587290998230447" STUDY_ID="STD-Xu-2009" TOTAL_1="27" TOTAL_2="21" VAR="0.22645502645502646" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="10" I2="0.0" ID="CMP-008.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2015-07-18 18:59:35 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Minimal response/no response</NAME>
<DICH_DATA CI_END="1.1871748830198596" CI_START="0.24968499361476212" EFFECT_SIZE="0.5444444444444444" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.07451469969264399" LOG_CI_START="-0.6026075585142666" LOG_EFFECT_SIZE="-0.26404642941081125" MODIFIED="2014-01-17 15:32:45 +1100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.3977449662799747" STUDY_ID="STD-Xu-2009" TOTAL_1="27" TOTAL_2="21" VAR="0.1582010582010582" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-07-30 11:01:19 +1000" MODIFIED_BY="Narelle S Willis">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-07-30 11:01:18 +1000" MODIFIED_BY="Narelle S Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow diagram of included and excluded study in Review</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApQAAAKVCAYAAABxk3uZAACAAElEQVR42uydD6QVzx/3vyRJkkiS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-07-30 11:01:19 +1000" MODIFIED_BY="Narelle S Willis" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias: Review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-07-30 11:01:19 +1000" MODIFIED_BY="Narelle S Willis" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias: Review authors' judgements about each risk of bias item for each included study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAVQAAAL5CAIAAABgmktPAAAnU0lEQVR42u3dvW4d1RrG8S0hIQoX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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-04-08 17:39:57 +1000" MODIFIED_BY="Narelle S Willis">
<APPENDIX ID="APP-01" MODIFIED="2009-04-08 17:38:21 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE MODIFIED="2008-06-16 17:49:46 +1000" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2009-04-08 17:38:21 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="4">
<TR>
<TH VALIGN="TOP">
<P>Database</P>
</TH>
<TH VALIGN="TOP">
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>MeSH descriptor Purpura, Schoenlein-Henoch, this term only</LI>
<LI>henoch next scho*nlein next purpura:ti,ab,kw</LI>
<LI>allergic next purpura:ti,ab,kw</LI>
<LI>anaphylactoid next purpura:ti,ab,kw</LI>
<LI>henoch next purpura:ti,ab,kw</LI>
<LI>nonthrombocytop*enic next purpura:ti,ab,kw</LI>
<LI>non next thrombocytop*enic next purpura:ti,ab,kw</LI>
<LI>leukocytoclastic next vasculitis:ti,ab,kw</LI>
<LI>peliosis next rheumatica:ti,ab,kw</LI>
<LI>purpura next rheumatica:ti,ab,kw</LI>
<LI>rheumatoid next purpura:ti,ab,kw</LI>
<LI>scho*nlein next disease:ti,ab,k</LI>
<LI>(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12)</LI>
</OL>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>Purpura, Schoenlein-Henoch/</LI>
<LI>henoch scho?nlein purpura.tw.</LI>
<LI>scho?nlein henoch purpura.tw.</LI>
<LI>allergic purpura.tw.</LI>
<LI>anaphylactoid purpura.tw.</LI>
<LI>henoch purpura.tw.</LI>
<LI>(nonthrombocytop?enic purpura or non thrombocytop?enic purpura).tw.</LI>
<LI>leukocytoclastic vasculitis.tw.</LI>
<LI>peliosis rheumatica.tw.</LI>
<LI>purpura rheumatica.tw.</LI>
<LI>rheumatoid purpura.tw.</LI>
<LI>scho?nlein disease.tw.</LI>
<LI>or/1-12</LI>
</OL>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD VALIGN="TOP">
<OL>
<LI>Anaphylactoid Purpura/</LI>
<LI>henoch scho?nlein.tw.</LI>
<LI>scho?nlein henoch.tw.</LI>
<LI>allergic purpura.tw.</LI>
<LI>anaphylactoid purpura.tw.</LI>
<LI>henoch purpura.tw.</LI>
<LI>nonthrombocytop?enic purpura.tw.</LI>
<LI>non thrombocytop?enic purpura.tw.</LI>
<LI>leukocytoclastic purpura.tw.</LI>
<LI>leukocytoclastic vasculitis.tw.</LI>
<LI>peliosis rheumatica.tw.</LI>
<LI>purpura rheumatica.tw.</LI>
<LI>rheumatoid purpura.tw.</LI>
<LI>scho?nlein disease.tw.</LI>
<LI>or/1-14</LI>
</OL>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-04-08 17:39:57 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2009-04-08 17:38:41 +1000" MODIFIED_BY="Narelle S Willis">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2009-04-08 17:39:57 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="2" ROWS="19">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Was there adequate sequence generation?</B>
</P>
</TD>
<TD>
<P>
<I>Yes (low risk of bias): </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>No (high risk of bias): </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Was allocation adequately concealed?</B>
</P>
</TD>
<TD>
<P>
<I>Yes (low risk of bias): </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>No (high risk of bias): </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Was knowledge of the allocated interventions adequately prevented during the study?</B>
</P>
</TD>
<TD>
<P>
<I>Yes (low risk of bias): </I>No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken; either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>No (high risk of bias): </I>No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken; either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No'</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Were incomplete outcome data adequately addressed?</B>
</P>
</TD>
<TD>
<P>
<I>Yes (low risk of bias): </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>No (high risk of bias): </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No'. </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Are reports of the study free of suggestion of selective outcome reporting?</B>
</P>
</TD>
<TD>
<P>
<I>Yes (low risk of bias): </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>No (high risk of bias): </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No'. </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Was the study apparently free of other problems that could put it at a risk of bias?</B>
</P>
</TD>
<TD>
<P>
<I>Yes (low risk of bias): </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>No (high risk of bias):</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No'. </P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>



<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;&lt;b&gt;Preventing HSP nephritis&lt;/b&gt;&lt;/p&gt;&lt;ol&gt;&lt;li&gt;Prednisone vs placebo/no treatment: 5 studies (856 enrolled participants)&lt;/li&gt;&lt;li&gt;Antiplatelet agents or heparin vs supportive therapy: 3 studies (357 enrolled participants)&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;&lt;b&gt;Treating severe HSP nephritis&lt;/b&gt;&lt;/p&gt;&lt;ol&gt;&lt;li&gt;Cyclophosphamide vs prednisone: 2 studies (110 enrolled participants)&lt;/li&gt;&lt;li&gt;Cyclosporin vs methylprednisolone: 1 study: (15 enrolled participants)&lt;/li&gt;&lt;li&gt;Mycophenolate mofetil vs azathioprine: 1 study (17 enrolled participants)&lt;/li&gt;&lt;li&gt;Fosinopril and standard therapy vs standard therapy: 1 study (48 enrolled participants)&lt;/li&gt;&lt;/ol&gt;" WIDTH="650">
<FLOWCHARTBOX TEXT="&lt;p&gt;2015 review update&lt;/p&gt;&lt;p&gt;Total included studies: 13 (26 reports)&lt;/p&gt;&lt;p&gt;Total excluded studies: 18 (20 reports)&lt;/p&gt;&lt;p&gt;Studies awaiting assessment: 4 (4 reports)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 10 (11 reports)&lt;/p&gt;&lt;p&gt;Excluded studies: 2 (2 reports)&lt;/p&gt;" WIDTH="250">
<FLOWCHARTBOX TEXT="&lt;p&gt;2009 review: 909 reports screened&lt;/p&gt;&lt;p&gt;MEDLINE, EMBASE, CENTRAL, Renal Register&lt;/p&gt;" WIDTH="300"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;New included studies: 3 (4 reports)&lt;/p&gt;&lt;p&gt;Existing included studies: 4 (10 new reports)&lt;/p&gt;&lt;p&gt;New excluded studies: 16 (17 reports; not RCT; wrong population; wrong intervention)&lt;/p&gt;&lt;p&gt;Studies awaiting classification: 4 (4 reports)&lt;/p&gt;" WIDTH="300">
<FLOWCHARTBOX TEXT="&lt;p&gt;2015 review update: 37 reports identified&lt;/p&gt;&lt;p&gt;Cochrane Kidney Transplant Register&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="300"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_16110_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="16110"><ADDRESS><DEPARTMENT>Sydney School of Public Health</DEPARTMENT><ORGANISATION>The University of Sydney</ORGANISATION><CITY>Sydney</CITY><ZIP>2006</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98453430</PHONE_1><FAX_1>+61 2 98453432</FAX_1></ADDRESS></ALIAS></EXTENSION><EXTENSION ID="AFF_9199_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="9199"><ADDRESS><DEPARTMENT>Sydney School of Public Health</DEPARTMENT><ORGANISATION>The University of Sydney</ORGANISATION><CITY>Sydney</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY></ADDRESS></ALIAS></EXTENSION><EXTENSION ID="AFF_4552_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="4552"><ADDRESS><DEPARTMENT>Cochrane Kidney and Transplant, Centre for Kidney Research</DEPARTMENT><ORGANISATION>The Children's Hospital at Westmead</ORGANISATION><CITY>Westmead</CITY><ZIP>2145</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 98451469</PHONE_1><FAX_1>+61 2 98451491</FAX_1></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>